<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T03:26:36Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8174225" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8174225</identifier>
        <datestamp>2021-06-11</datestamp>
        <setSpec>jaha</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Am Heart Assoc</journal-id>
              <journal-id journal-id-type="iso-abbrev">J Am Heart Assoc</journal-id>
              <journal-id journal-id-type="doi">10.1002/(ISSN)2047-9980</journal-id>
              <journal-id journal-id-type="publisher-id">JAH3</journal-id>
              <journal-id journal-id-type="hwp">ahaoa</journal-id>
              <journal-title-group>
                <journal-title>Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2047-9980</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8174225</article-id>
              <article-id pub-id-type="pmcid">PMC8174225</article-id>
              <article-id pub-id-type="pmc-uid">8174225</article-id>
              <article-id pub-id-type="pmid">33682431</article-id>
              <article-id pub-id-type="pmid">33682431</article-id>
              <article-id pub-id-type="doi">10.1161/JAHA.120.018744</article-id>
              <article-id pub-id-type="publisher-id">JAH36005</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Original Research</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Original Research</subject>
                  <subj-group subj-group-type="heading">
                    <subject>Coronary Heart Disease</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Prognosis of Claims‐ Versus Trial‐Based Ischemic and Bleeding Events Beyond 1 Year After Coronary Stenting</article-title>
                <alt-title alt-title-type="right-running-head">Prognosis of Events in Trial vs Claims</alt-title>
                <alt-title alt-title-type="left-running-head">Butala et al</alt-title>
              </title-group>
              <contrib-group>
                <contrib id="jah36005-cr-0001" contrib-type="author">
                  <name>
                    <surname>Butala</surname>
                    <given-names>Neel M.</given-names>
                  </name>
                  <degrees>MD, MBA</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6937-4041</contrib-id>
                  <xref ref-type="aff" rid="jah36005-aff-0001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="jah36005-aff-0002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah36005-cr-0002" contrib-type="author">
                  <name>
                    <surname>Faridi</surname>
                    <given-names>Kamil F.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9276-9110</contrib-id>
                  <xref ref-type="aff" rid="jah36005-aff-0003">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="jah36005-cr-0003" contrib-type="author">
                  <name>
                    <surname>Secemsky</surname>
                    <given-names>Eric A.</given-names>
                  </name>
                  <degrees>MD, MSc</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3861-3163</contrib-id>
                  <xref ref-type="aff" rid="jah36005-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jah36005-cr-0004" contrib-type="author">
                  <name>
                    <surname>Song</surname>
                    <given-names>Yang</given-names>
                  </name>
                  <degrees>MS</degrees>
                  <xref ref-type="aff" rid="jah36005-aff-0004">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib id="jah36005-cr-0005" contrib-type="author">
                  <name>
                    <surname>Curtis</surname>
                    <given-names>Jeptha</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="jah36005-aff-0003">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="jah36005-cr-0006" contrib-type="author">
                  <name>
                    <surname>Gibson</surname>
                    <given-names>Charles Michael</given-names>
                  </name>
                  <degrees>MD, MS</degrees>
                  <xref ref-type="aff" rid="jah36005-aff-0004">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib id="jah36005-cr-0007" contrib-type="author">
                  <name>
                    <surname>Kazi</surname>
                    <given-names>Dhruv</given-names>
                  </name>
                  <degrees>MD, MS</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9510-2979</contrib-id>
                  <xref ref-type="aff" rid="jah36005-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jah36005-cr-0008" contrib-type="author">
                  <name>
                    <surname>Shen</surname>
                    <given-names>Changyu</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="jah36005-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jah36005-cr-0009" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Yeh</surname>
                    <given-names>Robert W.</given-names>
                  </name>
                  <degrees>MD, MSc</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0564-4468</contrib-id>
                  <xref ref-type="aff" rid="jah36005-aff-0001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="jah36005-aff-0004">
                    <sup>4</sup>
                  </xref>
                  <address>
                    <email>ryeh@bidmc.harvard.edu</email>
                  </address>
                </contrib>
              </contrib-group>
              <aff id="jah36005-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <named-content content-type="organisation-division">Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology</named-content>
                <named-content content-type="organisation-division">Division of Cardiovascular Medicine</named-content>
                <institution>Beth Israel Deaconess Medical Center</institution>
                <city>Boston</city>
                <named-content content-type="country-part">MA</named-content>
              </aff>
              <aff id="jah36005-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <named-content content-type="organisation-division">Cardiology Division</named-content>
                <named-content content-type="organisation-division">Department of Medicine</named-content>
                <institution>Massachusetts General Hospital</institution>
                <institution>Harvard Medical School</institution>
                <city>Boston</city>
                <named-content content-type="country-part">MA</named-content>
              </aff>
              <aff id="jah36005-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <named-content content-type="organisation-division">Section of Cardiovascular Medicine</named-content>
                <named-content content-type="organisation-division">Department of Medicine</named-content>
                <institution>Yale School of Medicine</institution>
                <city>New Haven</city>
                <named-content content-type="country-part">CT</named-content>
              </aff>
              <aff id="jah36005-aff-0004">
                <label>
                  <sup>4</sup>
                </label>
                <institution>Baim Institute for Clinical Research</institution>
                <city>Boston</city>
                <named-content content-type="country-part">MA</named-content>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label>
Correspondence to: Robert W. Yeh, MD MSc, Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Department of Medicine, Division of Cardiovascular Disease, Beth Israel Deaconess Medical Center, 375 Longwood Ave, Boston, MA 02215, USA. E‐mail: <email>ryeh@bidmc.harvard.edu</email><break/></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>06</day>
                <month>3</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="collection">
                <day>16</day>
                <month>3</month>
                <year>2021</year>
              </pub-date>
              <volume>10</volume>
              <issue>6</issue>
              <issue-id pub-id-type="doi">10.1002/jah3.v10.6</issue-id>
              <elocation-id>e018744</elocation-id>
              <history>
                <date date-type="received">
                  <day>23</day>
                  <month>9</month>
                  <year>2020</year>
                </date>
                <date date-type="accepted">
                  <day>11</day>
                  <month>1</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <!--<copyright-statement content-type="issue-copyright">Copyright &#x000a9; 2021 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell<copyright-statement>-->
                <copyright-statement content-type="article-copyright">© 2021 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="file:JAH3-10-e018744.pdf"/>
              <abstract id="jah36005-abs-0001">
                <sec id="jah36005-sec-0001">
                  <title>Background</title>
                  <p>It is unknown whether clinical events identified with administrative claims have similar prognosis compared with trial‐adjudicated events in cardiovascular clinical trials. We compared the prognostic significance of claims‐based end points in context of trial‐adjudicated end points in the DAPT (Dual Antiplatelet Therapy) study.</p>
                </sec>
                <sec id="jah36005-sec-0002">
                  <title>Methods and Results</title>
                  <p>We matched 1336 patients aged ≥65 years who received percutaneous coronary intervention in the DAPT study with the CathPCI registry linked to Medicare claims. We compared death at 21 months post‐randomization using Cox proportional hazards models among patients with ischemic events (myocardial infarction or stroke) and bleeding events identified by: (1) both trial adjudication and claims; (2) trial adjudication only; and (3) claims only. A total of 47 patients (3.5%) had ischemic events identified by both trial adjudication and claims, 24 (1.8%) in trial adjudication only, 15 (1.1%) in claims only, and 1250 (93.6%) had no ischemic events, with annualized unadjusted mortality rates of 12.8, 5.5, 14.9, and 1.26 per 100 person‐years, respectively. A total of 44 patients (3.3%) had bleeding events identified with both trial adjudication and claims, 13 (1.0%) in trial adjudication only, 65 (4.9%) in claims only, and 1214 (90.9%) had no bleeding events, with annualized unadjusted mortality rates of 11.0, 16.8, 10.7, and 0.95 per 100 person‐years, respectively. Among patients with no trial‐adjudicated events, patients with events in claims only had a high subsequent adjusted mortality risk (hazard ratio (HR) ischemic events: 31.5; 95% CI, 8.9‒111.9; HR bleeding events 23.9; 95% CI, 10.7‒53.2).</p>
                </sec>
                <sec id="jah36005-sec-0003">
                  <title>Conclusions</title>
                  <p>In addition to trial‐adjudicated events, claims identified additional clinically meaningful ischemic and bleeding events that were prognostically significant for death.</p>
                </sec>
              </abstract>
              <kwd-group>
                <kwd id="jah36005-kwd-0001">claims</kwd>
                <kwd id="jah36005-kwd-0002">clinical trials</kwd>
                <kwd id="jah36005-kwd-0003">DAPT</kwd>
                <kwd id="jah36005-kwd-0004">end points</kwd>
                <kwd id="jah36005-kwd-0005">prognosis</kwd>
              </kwd-group>
              <kwd-group kwd-group-type="subject-categories">
                <title>Subject Categories</title>
                <kwd>Mortality/Survival</kwd>
              </kwd-group>
              <funding-group>
                <award-group id="funding-0001">
                  <funding-source>
                    <institution-wrap>
                      <institution>National Heart, Lung, and Blood Institute </institution>
                      <institution-id institution-id-type="open-funder-registry">10.13039/100000050</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>1R01HL136708</award-id>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="2"/>
                <table-count count="2"/>
                <page-count count="11"/>
                <word-count count="7788"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>March 16, 2021</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.0.1 mode:remove_FC converted:09.04.2021</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <p content-type="self-citation">
                <mixed-citation publication-type="journal" id="jah36005-cit-1001">(<source xml:lang="en">J Am Heart Assoc</source>. <year>2021</year>;<volume>10</volume>:<elocation-id>e018744</elocation-id>. DOI: <pub-id pub-id-type="doi">10.1161/JAHA.120.018744</pub-id>.)<pub-id pub-id-type="pmid">33682431</pub-id></mixed-citation>
              </p>
              <fn-group id="jah36005-ntgp-0001">
                <fn id="jah36005-note-0100">
                  <p>Supplementary Material for this article is available at <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/JAHA.120.018744">https://www.ahajournals.org/doi/suppl/10.1161/JAHA.120.018744</ext-link>
</p>
                </fn>
                <fn id="jah36005-note-0001">
                  <p>For Sources of Funding and Disclosures, see page 10.</p>
                </fn>
              </fn-group>
            </notes>
          </front>
          <body id="jah36005-body-0001">
            <def-list list-content="abbreviations" id="jah36005-lp-0001">
              <title>Nonstandard Abbreviations and Acronyms</title>
              <def-item>
                <term>DAPT</term>
                <def>
                  <p>dual antiplatelet therapy</p>
                </def>
              </def-item>
              <def-item>
                <term>NCDR</term>
                <def>
                  <p>national cardiovascular data registry</p>
                </def>
              </def-item>
            </def-list>
            <p>
              <boxed-text position="anchor" content-type="box" id="jah36005-blkfxd-0001" orientation="portrait">
                <sec id="jah36005-sec-0005">
                  <title>Clinical Perspective</title>
                </sec>
                <sec id="jah36005-sec-0006">
                  <title>What Is New?</title>
                  <p>
                    <list list-type="bullet" id="jah36005-list-0001">
                      <list-item>
                        <p>In addition to trial‐adjudicated events in the DAPT (Dual Antiplatelet Therapy) study, administrative claims identified additional clinically meaningful ischemic and bleeding events that were prognostically significant for death.</p>
                      </list-item>
                    </list>
                  </p>
                </sec>
                <sec id="jah36005-sec-0007">
                  <title>What Are the Clinical Implications?</title>
                  <p>
                    <list list-type="bullet" id="jah36005-list-0002">
                      <list-item>
                        <p>These results demonstrate the incremental value of claims‐based end points in identifying additional clinically meaningful events for subsequent adjudication in clinical trials and support the use of claims to augment clinical trial end point ascertainment in future cardiovascular clinical trials.</p>
                      </list-item>
                    </list>
                  </p>
                </sec>
              </boxed-text>
            </p>
            <sec sec-type="opening-section" id="jah36005-sec-0008">
              <p>Real‐world data are rapidly changing the conduct of cardiovascular clinical trials. Large‐scale trials have leveraged real‐world data from registries and wearable devices to generate clinical evidence.<xref rid="jah36005-bib-0001" ref-type="ref"><sup>1</sup></xref>, <xref rid="jah36005-bib-0002" ref-type="ref"><sup>2</sup></xref> Furthermore, the US Food and Drug Administration evaluates evidence from real‐world data to support regulatory decision‐making, including the approval of new drugs.<xref rid="jah36005-bib-0003" ref-type="ref"><sup>3</sup></xref> The use of administrative claims data to ascertain outcomes in cardiovascular clinical trials offers opportunity to improve clinical trial data collection and reduce trial costs.<xref rid="jah36005-bib-0004" ref-type="ref"><sup>4</sup></xref>, <xref rid="jah36005-bib-0005" ref-type="ref"><sup>5</sup></xref>, <xref rid="jah36005-bib-0006" ref-type="ref"><sup>6</sup></xref> However, it is unknown whether clinical events identified with claims data have similar prognoses compared with traditional, trial‐adjudicated clinical events.</p>
              <p>Understanding the significance of clinical events is particularly important after percutaneous coronary intervention (PCI), where subtle changes in definitions of trial end points can lead to differences in patient prognosis and trial results.<xref rid="jah36005-bib-0007" ref-type="ref"><sup>7</sup></xref>, <xref rid="jah36005-bib-0008" ref-type="ref"><sup>8</sup></xref>, <xref rid="jah36005-bib-0009" ref-type="ref"><sup>9</sup></xref> Both spontaneous bleeding and myocardial infarction (MI) after PCI are associated with increased long‐term mortality.<xref rid="jah36005-bib-0010" ref-type="ref"><sup>10</sup></xref>, <xref rid="jah36005-bib-0011" ref-type="ref"><sup>11</sup></xref> Furthermore, in patients treated with dual antiplatelet therapy for at least 1 year after PCI in the DAPT (Dual Antiplatelet Therapy) study, late ischemic events and bleeding events were both associated with a high risk of mortality.<xref rid="jah36005-bib-0012" ref-type="ref"><sup>12</sup></xref> The prognostic significance of claims‐based events in comparison with trial‐adjudicated events in this clinical context is unknown.</p>
              <p>In this study, we compared the prognostic significance of claims‐based ischemic and bleeding end points in context of trial‐adjudicated ischemic and bleeding end points in the DAPT study. Such results can inform the use of claims‐based end points for evaluation of clinical events post‐PCI and thereby shed light on the clinical use of claims‐based end points in cardiovascular clinical trials more broadly.</p>
            </sec>
            <sec sec-type="methods" id="jah36005-sec-0009">
              <title>METHODS</title>
              <sec id="jah36005-sec-0010">
                <title>EXTEND‐DAPT Study Overview</title>
                <p>This analysis was performed as part of the Extending Trial‐Based Evaluations of Medical Therapies Using Novel Sources of Data (EXTEND) Study, which is funded by the National Heart, Lung, and Blood Institute (1R01HL136708). An overview of the aims and methods, including data linkage, has been previously described.<xref rid="jah36005-bib-0013" ref-type="ref"><sup>13</sup></xref> The EXTEND‐DAPT sub‐study used data from the DAPT study linked to the American College of Cardiology's NCDR (National Cardiovascular Data Registry) CathPCI Registry and Medicare fee‐for‐service beneficiary claims.</p>
                <p>The DAPT study was a randomized, placebo‐controlled clinical trial which enrolled patients who underwent percutaneous coronary intervention and received DAPT consisting of aspirin and a thienopyridine for 1 year.<xref rid="jah36005-bib-0014" ref-type="ref"><sup>14</sup></xref> At 12 months following PCI, patients without post‐PCI ischemic or bleeding events were randomized to either placebo (12 total months of DAPT) or continued thienopyridine for another 18 months (30 total months of DAPT). The trial was conducted by the Baim Institute for Clinical Research.</p>
              </sec>
              <sec id="jah36005-sec-0011">
                <title>Study Population</title>
                <p>We included all US patients aged ≥65 years in the DAPT study who could be successfully linked via the NCDR CathPCI registry to the Centers for Medicare and Medicaid Services inpatient claims data for all fee‐for‐service Medicare‐insured patients. Linkage was performed using deterministic algorithms based on age or date of birth, sex, PCI date and stent type, hospital discharge date, and hospital identifiers and has been previously described.<xref rid="jah36005-bib-0013" ref-type="ref"><sup>13</sup></xref> These data were also linked to the Medicare Master Beneficiary Summary File to determine dates of death. Patients who could not be linked to the CathPCI registry because of inexact matching characteristics or who were not subsequently found in Centers for Medicare and Medicaid Services fee‐for‐service claims or the Medicare Master Beneficiary Summary File were excluded. After applying these criteria to 11 648 patients randomized in the DAPT study, a total of 1336 individuals were included in the linked EXTEND‐DAPT cohort (Figure <xref rid="jah36005-sup-0001" ref-type="supplementary-material">S1</xref>). Patients were excluded because of age &lt;65 years (5984 patients), patients outside of the United States (1756 patients), lack of corresponding record in the CathPCI registry (1350 patients), lack of corresponding record in Medicare data (530 patients), and insurance coverage with Medicare Advantage (692 patients). Notably, US patients aged ≥65 years who were able to be successfully matched to the Centers for Medicare and Medicaid Services master file were similar to unmatched patients with regard to most measured covariates, apart from being more often women, having a higher rate of peripheral artery disease, and more often presenting initially with stable angina (Table <xref rid="jah36005-sup-0001" ref-type="supplementary-material">S1</xref>).<xref rid="jah36005-bib-0015" ref-type="ref"><sup>15</sup></xref>
</p>
                <p>All baseline characteristics were obtained from information collected in the DAPT study. The study period was from time of randomization (12 months following PCI) to 21 months post‐randomization (33 months following PCI), as specified in the DAPT study. This study was approved by the institutional review board at Beth Israel Deaconess Medical Center and the requirement for informed consent was waived because of retrospective analysis of pre‐existing data.</p>
              </sec>
              <sec id="jah36005-sec-0012">
                <title>Study Variables</title>
                <p>The primary outcome was death at 21 months after randomization (33 months after coronary stenting) as captured in the DAPT study.</p>
                <p>The primary exposures were ischemic events (MI and non‐hemorrhagic stroke) and bleeding events occurring 12 to 33 months after coronary stenting in trial data and in claims.</p>
                <p>Clinical events in trial data were determined based on adjudication by the DAPT study Clinical Events Committee, which was blinded to randomization status. The trial used pre‐specified definitions of MI and stroke for adjudication.<xref rid="jah36005-bib-0016" ref-type="ref"><sup>16</sup></xref> Major bleeding in this study was defined as any adjudicated event that met criteria for either moderate or severe bleeding according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries classification, or Type 3 or 5 bleeding according to the Bleeding Academic Research Consortium.</p>
                <p>Clinical events in administrative claims were defined based on a comprehensive list of previously validated <italic>International Classification of Diseases, Ninth Revision, Clinical Modification</italic> (<italic>ICD‐9</italic>) diagnosis codes associated with inpatient hospitalizations.<xref rid="jah36005-bib-0015" ref-type="ref"><sup>15</sup></xref>, <xref rid="jah36005-bib-0017" ref-type="ref"><sup>17</sup></xref> For each outcome, we identified <italic>ICD‐9</italic> codes based on clinical relevance as well as prior literature (Table <xref rid="jah36005-sup-0001" ref-type="supplementary-material">S2</xref>).<xref rid="jah36005-bib-0018" ref-type="ref"><sup>18</sup></xref>, <xref rid="jah36005-bib-0019" ref-type="ref"><sup>19</sup></xref>, <xref rid="jah36005-bib-0020" ref-type="ref"><sup>20</sup></xref>, <xref rid="jah36005-bib-0021" ref-type="ref"><sup>21</sup></xref>, <xref rid="jah36005-bib-0022" ref-type="ref"><sup>22</sup></xref> Given that transfusions were included in trial definitions of bleeding, <italic>ICD‐9</italic> procedure codes for blood transfusions were also used. An event was counted if the corresponding codes were present in either the primary or secondary billing position during the hospitalization associated with the event. An event in claims data was counted as a match with a Clinical Events Committee‐adjudicated event if the hospitalization admission date occurred within 14 days of the event date determined in the trial.</p>
              </sec>
              <sec id="jah36005-sec-0013">
                <title>Statistical Analysis</title>
                <p>We compared characteristics and outcomes among 4 groups: (1) those with clinical events identified in both the trial and claims; (2) those with clinical events identified in the trial only; (3) those with clinical events identified in claims only; and (4) those with no clinical events. Categorical variables were reported as counts and percentages, and continuous variables were reported as means (SDs). Between‐group differences were assessed using an ANOVA test for continuous variables or a Pearson χ2 test for categorical variables.</p>
                <p>Among the randomized study population, we examined (1) the number of patients with ischemic and bleeding events after randomization in both the trial and in claims‐based measures and (2) the annualized mortality rate per 100 person‐years after each event. Patients experiencing both ischemic and bleeding events contributed data to both the ischemic events groups and the bleeding events groups; however, for patients with &gt;1 of the same type of event in the trial or in claims, only the earliest event was included.</p>
                <p>Cox proportional hazards regression models with exposure status as a time‐dependent variable were created to evaluate the independent association of ischemic events or bleeding events with mortality. The time‐updated models allowed for patients to contribute both unexposed (ie, before event) and exposed (ie, after event) person‐time. Given the limited sample size, ischemic events and bleeding events models were adjusted for a single variable indicating the predicted probability of having ischemic events or bleeding events, respectively, at 21 months using previously developed risk adjustment models that formed the basis of the DAPT score.<xref rid="jah36005-bib-0023" ref-type="ref"><sup>23</sup></xref> Hazard ratios (HRs) among different pairs of groups were compared using a Wald test as well as a global Chi‐squared statistic and Wald test.</p>
                <p>In a supplemental post‐hoc analysis, we examined the percentage of patients with claims‐only events who had Bleeding Academic Research Consortium Type 2 bleeding events. We additionally compared the annualized mortality rates among any patients with ischemic or bleeding events in trials and all patients with ischemic or bleeding events in claims, including patients with bleeding events in both trials and claims in both groups. Statistical analyses were performed using a software program (SAS, version 9.4; SAS Institute Inc).</p>
              </sec>
            </sec>
            <sec sec-type="results" id="jah36005-sec-0014">
              <title>RESULTS</title>
              <p>Of the 1336 patients in the EXTEND‐DAPT cohort, 47 patients (3.5%) had ischemic events identified with both trial adjudication and claims, 24 (1.8%) had trial‐adjudicated ischemic events only, 15 (1.1%) had ischemic events in claims only, and 1250 (93.6%) had no ischemic events (Figure <xref rid="jah36005-fig-0001" ref-type="fig">1A</xref>). These 4 groups of patients had similar baseline characteristics with the exception of treated vessel and drug‐eluting stent type (Table <xref rid="jah36005-tbl-0001" ref-type="table">1</xref>). A total of 44 patients (3.3%) had bleeding events identified with both trial adjudication and claims, 13 (1.0%) had trial‐adjudicated bleeding events only, 65 (4.9%) had bleeding events in claims only, and 1214 (90.9%) had no bleeding events (Figure <xref rid="jah36005-fig-0001" ref-type="fig">1B</xref>). Notably, of the 65 patients with bleeding events in claims alone, 18 (28%) had Bleeding Academic Research Consortium Type 2 bleeding events in the trial data. These 4 groups of patients also had similar baseline characteristics with the exception of presentation with stable angina and treated vessel (Table <xref rid="jah36005-tbl-0002" ref-type="table">2</xref>).</p>
              <fig fig-type="Figure" xml:lang="en" id="jah36005-fig-0001" orientation="portrait" position="float">
                <label>Figure 1</label>
                <caption>
                  <title>Frequency of ischemic and bleeding events in trial vs claims and subsequent annualized mortality rate during the 21‐month post‐randomization period.</title>
                  <p>(<bold>A</bold>) Ischemic events; (<bold>B</bold>) Bleeding events. The annualized rate was calculated as: (number of subjects who died after a clinical event)/(total follow‐up years for each of the 3 cohorts after a clinical event). For the 'no event' group, the annualized mortality rate is calculated as: (number of subjects who died/total follow‐up years). Error bars indicate 95% CIs.</p>
                </caption>
                <graphic id="jats-graphic-1" xlink:href="JAH3-10-e018744-g002"/>
              </fig>
              <table-wrap id="jah36005-tbl-0001" xml:lang="en" content-type="Table" orientation="portrait" position="float">
                <label>Table 1</label>
                <caption>
                  <p>Baseline Characteristics of Patients With Ischemic Events in Trials and Claims Data</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <thead valign="top">
                    <tr style="border-bottom:solid 1px #000000">
                      <th align="left" valign="top" rowspan="1" colspan="1">Characteristics</th>
                      <th align="center" valign="top" rowspan="1" colspan="1">
                        <p>Event in Both Trial and Claims</p>
                        <p>(n=47)</p>
                      </th>
                      <th align="center" valign="top" rowspan="1" colspan="1">
                        <p>Event in Trial Only</p>
                        <p>(n=24)</p>
                      </th>
                      <th align="center" valign="top" rowspan="1" colspan="1">
                        <p>Event in Claims Only</p>
                        <p>(n=15)</p>
                      </th>
                      <th align="center" valign="top" rowspan="1" colspan="1">
                        <p>No Event</p>
                        <p>(n=1250)</p>
                      </th>
                      <th align="center" valign="top" rowspan="1" colspan="1"><italic>P</italic> Value<xref ref-type="fn" rid="jah36005-note-0003">*</xref>
</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td align="left" colspan="6" rowspan="1">Clinical characteristics</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" colspan="6" rowspan="1">Age, y</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Mean±SD, n</td>
                      <td align="left" rowspan="1" colspan="1">72.3±6.3 (47)</td>
                      <td align="left" rowspan="1" colspan="1">71.0±4.2 (24)</td>
                      <td align="left" rowspan="1" colspan="1">73.9±5.4 (15)</td>
                      <td align="left" rowspan="1" colspan="1">71.8±5.5 (1250)</td>
                      <td align="left" rowspan="3" colspan="1">0.312</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Median (Q1, Q3)</td>
                      <td align="left" rowspan="1" colspan="1">71.0 (67.1, 74.0)</td>
                      <td align="left" rowspan="1" colspan="1">70.3 (68.0, 74.5)</td>
                      <td align="left" rowspan="1" colspan="1">73.0 (69.0, 76.0)</td>
                      <td align="left" rowspan="1" colspan="1">71.0 (67.0, 75.0)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Range (min, max)</td>
                      <td align="left" rowspan="1" colspan="1">(65.0, 89.0)</td>
                      <td align="left" rowspan="1" colspan="1">(65.0, 80.0)</td>
                      <td align="left" rowspan="1" colspan="1">(65.0, 84.0)</td>
                      <td align="left" rowspan="1" colspan="1">(65.0, 91.0)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Women</td>
                      <td align="left" rowspan="1" colspan="1">38.3% (18/47)</td>
                      <td align="left" rowspan="1" colspan="1">33.3% (8/24)</td>
                      <td align="left" rowspan="1" colspan="1">33.3% (5/15)</td>
                      <td align="left" rowspan="1" colspan="1">32.5% (406/1250)</td>
                      <td align="left" rowspan="1" colspan="1">0.954</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" colspan="6" rowspan="1">Race</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">American Indian or Alaska Native</td>
                      <td align="left" rowspan="1" colspan="1">0.0% (0/47)</td>
                      <td align="left" rowspan="1" colspan="1">0.0% (0/24)</td>
                      <td align="left" rowspan="1" colspan="1">0.0% (0/15)</td>
                      <td align="left" rowspan="1" colspan="1">0.2% (3/1244)</td>
                      <td align="left" rowspan="6" colspan="1">0.691</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Asian</td>
                      <td align="left" rowspan="1" colspan="1">0.0% (0/47)</td>
                      <td align="left" rowspan="1" colspan="1">0.0% (0/24)</td>
                      <td align="left" rowspan="1" colspan="1">0.0% (0/15)</td>
                      <td align="left" rowspan="1" colspan="1">0.6% (8/1244)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Black</td>
                      <td align="left" rowspan="1" colspan="1">4.3% (2/47)</td>
                      <td align="left" rowspan="1" colspan="1">4.2% (1/24)</td>
                      <td align="left" rowspan="1" colspan="1">0.0% (0/15)</td>
                      <td align="left" rowspan="1" colspan="1">3.9% (48/1244)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Native Hawaiian or Other Pacific Islander</td>
                      <td align="left" rowspan="1" colspan="1">0.0% (0/47)</td>
                      <td align="left" rowspan="1" colspan="1">0.0% (0/24)</td>
                      <td align="left" rowspan="1" colspan="1">0.0% (0/15)</td>
                      <td align="left" rowspan="1" colspan="1">0.2% (2/1244)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">White</td>
                      <td align="left" rowspan="1" colspan="1">93.6% (44/47)</td>
                      <td align="left" rowspan="1" colspan="1">87.5% (21/24)</td>
                      <td align="left" rowspan="1" colspan="1">100.0% (15/15)</td>
                      <td align="left" rowspan="1" colspan="1">93.4% (1162/1244)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Other</td>
                      <td align="left" rowspan="1" colspan="1">2.1% (1/47)</td>
                      <td align="left" rowspan="1" colspan="1">8.3% (2/24)</td>
                      <td align="left" rowspan="1" colspan="1">0.0% (0/15)</td>
                      <td align="left" rowspan="1" colspan="1">1.7% (21/1244)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hispanic or Latino</td>
                      <td align="left" rowspan="1" colspan="1">2.2% (1/46)</td>
                      <td align="left" rowspan="1" colspan="1">12.5% (3/24)</td>
                      <td align="left" rowspan="1" colspan="1">0.0% (0/14)</td>
                      <td align="left" rowspan="1" colspan="1">2.3% (29/1246)</td>
                      <td align="left" rowspan="1" colspan="1">0.095</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" colspan="6" rowspan="1">Body mass index, Kg/m<sup>2</sup>
</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Mean±SD, n</td>
                      <td align="left" rowspan="1" colspan="1">29.3±.2 (47)</td>
                      <td align="left" rowspan="1" colspan="1">29.3±6.0 (24)</td>
                      <td align="left" rowspan="1" colspan="1">27.9±3.7 (15)</td>
                      <td align="left" rowspan="1" colspan="1">29.7±5.3 (1250)</td>
                      <td align="left" rowspan="3" colspan="1">0.650</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Median (Q1, Q3)</td>
                      <td align="left" rowspan="1" colspan="1">28.6 (25.6, 31.3)</td>
                      <td align="left" rowspan="1" colspan="1">28.3 (25.8, 32.3)</td>
                      <td align="left" rowspan="1" colspan="1">26.9 (24.8, 31.2)</td>
                      <td align="left" rowspan="1" colspan="1">29.0 (26.0, 32.5)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Range (min, max)</td>
                      <td align="left" rowspan="1" colspan="1">(22.0, 46.3)</td>
                      <td align="left" rowspan="1" colspan="1">(20.8, 43.0)</td>
                      <td align="left" rowspan="1" colspan="1">(22.0, 35.0)</td>
                      <td align="left" rowspan="1" colspan="1">(15.7, 52.2)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Diabetes mellitus</td>
                      <td align="left" rowspan="1" colspan="1">46.8% (22/47)</td>
                      <td align="left" rowspan="1" colspan="1">52.2% (12/23)</td>
                      <td align="left" rowspan="1" colspan="1">26.7% (4/15)</td>
                      <td align="left" rowspan="1" colspan="1">32.4% (405/1249)</td>
                      <td align="left" rowspan="1" colspan="1">0.290</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Insulin</td>
                      <td align="left" rowspan="1" colspan="1">21.3% (10/47)</td>
                      <td align="left" rowspan="1" colspan="1">13.0% (3/23)</td>
                      <td align="left" rowspan="1" colspan="1">0.0% (0/15)</td>
                      <td align="left" rowspan="1" colspan="1">8.1% (101/1249)</td>
                      <td align="left" rowspan="1" colspan="1">0.144</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Oral medications</td>
                      <td align="left" rowspan="1" colspan="1">21.3% (10/47)</td>
                      <td align="left" rowspan="1" colspan="1">34.8% (8/23)</td>
                      <td align="left" rowspan="1" colspan="1">20.0% (3/15)</td>
                      <td align="left" rowspan="1" colspan="1">20.7% (258/1249)</td>
                      <td align="left" rowspan="1" colspan="1">0.428</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Diet controlled or no treatment</td>
                      <td align="left" rowspan="1" colspan="1">4.3% (2/47)</td>
                      <td align="left" rowspan="1" colspan="1">4.3% (1/23)</td>
                      <td align="left" rowspan="1" colspan="1">6.7% (1/15)</td>
                      <td align="left" rowspan="1" colspan="1">3.7% (46/1249)</td>
                      <td align="left" rowspan="1" colspan="1">1.000</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hypertension</td>
                      <td align="left" rowspan="1" colspan="1">89.4% (42/47)</td>
                      <td align="left" rowspan="1" colspan="1">83.3% (20/24)</td>
                      <td align="left" rowspan="1" colspan="1">100.0% (15/15)</td>
                      <td align="left" rowspan="1" colspan="1">84.8% (1057/1246)</td>
                      <td align="left" rowspan="1" colspan="1">0.244</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Peripheral artery disease</td>
                      <td align="left" rowspan="1" colspan="1">17.0% (8/47)</td>
                      <td align="left" rowspan="1" colspan="1">18.2% (4/22)</td>
                      <td align="left" rowspan="1" colspan="1">6.7% (1/15)</td>
                      <td align="left" rowspan="1" colspan="1">10.1% (124/1233)</td>
                      <td align="left" rowspan="1" colspan="1">0.714</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Congestive heart failure</td>
                      <td align="left" rowspan="1" colspan="1">19.1% (9/47)</td>
                      <td align="left" rowspan="1" colspan="1">8.3% (2/24)</td>
                      <td align="left" rowspan="1" colspan="1">13.3% (2/15)</td>
                      <td align="left" rowspan="1" colspan="1">5.8% (72/1241)</td>
                      <td align="left" rowspan="1" colspan="1">0.510</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Previous myocardial infarction</td>
                      <td align="left" rowspan="1" colspan="1">22.2% (10/45)</td>
                      <td align="left" rowspan="1" colspan="1">34.8% (8/23)</td>
                      <td align="left" rowspan="1" colspan="1">33.3% (5/15)</td>
                      <td align="left" rowspan="1" colspan="1">20.5% (250/1217)</td>
                      <td align="left" rowspan="1" colspan="1">0.481</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Stroke/transient ischemic event</td>
                      <td align="left" rowspan="1" colspan="1">6.4% (3/47)</td>
                      <td align="left" rowspan="1" colspan="1">0.0% (0/22)</td>
                      <td align="left" rowspan="1" colspan="1">6.7% (1/15)</td>
                      <td align="left" rowspan="1" colspan="1">5.4% (68/1249)</td>
                      <td align="left" rowspan="1" colspan="1">0.501</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" colspan="6" rowspan="1">Prior procedures</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Previous percutaneous coronary intervention</td>
                      <td align="left" rowspan="1" colspan="1">46.8% (22/47)</td>
                      <td align="left" rowspan="1" colspan="1">58.3% (14/24)</td>
                      <td align="left" rowspan="1" colspan="1">53.3% (8/15)</td>
                      <td align="left" rowspan="1" colspan="1">34.1% (424/1242)</td>
                      <td align="left" rowspan="1" colspan="1">0.673</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Coronary artery bypass graft</td>
                      <td align="left" rowspan="1" colspan="1">23.4% (11/47)</td>
                      <td align="left" rowspan="1" colspan="1">20.8% (5/24)</td>
                      <td align="left" rowspan="1" colspan="1">20.0% (3/15)</td>
                      <td align="left" rowspan="1" colspan="1">16.2% (202/1248)</td>
                      <td align="left" rowspan="1" colspan="1">1.000</td>
                    </tr>
                    <tr>
                      <td align="left" colspan="6" rowspan="1">Indication for index procedure</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Acute coronary syndrome</td>
                      <td align="left" rowspan="1" colspan="1">25.5% (12/47)</td>
                      <td align="left" rowspan="1" colspan="1">16.7% (4/24)</td>
                      <td align="left" rowspan="1" colspan="1">13.3% (2/15)</td>
                      <td align="left" rowspan="1" colspan="1">14.7% (184/1250)</td>
                      <td align="left" rowspan="1" colspan="1">0.625</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">STEMI</td>
                      <td align="left" rowspan="1" colspan="1">0.0% (0/47)</td>
                      <td align="left" rowspan="1" colspan="1">0.0% (0/24)</td>
                      <td align="left" rowspan="1" colspan="1">6.7% (1/15)</td>
                      <td align="left" rowspan="1" colspan="1">4.2% (52/1250)</td>
                      <td align="left" rowspan="1" colspan="1">0.174</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">NSTEMI</td>
                      <td align="left" rowspan="1" colspan="1">25.5% (12/47)</td>
                      <td align="left" rowspan="1" colspan="1">16.7% (4/24)</td>
                      <td align="left" rowspan="1" colspan="1">6.7% (1/15)</td>
                      <td align="left" rowspan="1" colspan="1">10.6% (132/1250)</td>
                      <td align="left" rowspan="1" colspan="1">0.306</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Unstable angina<sup>3</sup>
</td>
                      <td align="left" rowspan="1" colspan="1">12.8% (6/47)</td>
                      <td align="left" rowspan="1" colspan="1">16.7% (4/24)</td>
                      <td align="left" rowspan="1" colspan="1">6.7% (1/15)</td>
                      <td align="left" rowspan="1" colspan="1">15.2% (190/1250)</td>
                      <td align="left" rowspan="1" colspan="1">0.754</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Stable angina</td>
                      <td align="left" rowspan="1" colspan="1">31.9% (15/47)</td>
                      <td align="left" rowspan="1" colspan="1">37.5% (9/24)</td>
                      <td align="left" rowspan="1" colspan="1">66.7% (10/15)</td>
                      <td align="left" rowspan="1" colspan="1">45.4% (568/1250)</td>
                      <td align="left" rowspan="1" colspan="1">0.060</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Other</td>
                      <td align="left" rowspan="1" colspan="1">29.8% (14/47)</td>
                      <td align="left" rowspan="1" colspan="1">29.2% (7/24)</td>
                      <td align="left" rowspan="1" colspan="1">13.3% (2/15)</td>
                      <td align="left" rowspan="1" colspan="1">24.6% (308/1250)</td>
                      <td align="left" rowspan="1" colspan="1">0.534</td>
                    </tr>
                    <tr>
                      <td align="left" colspan="6" rowspan="1">Procedural characteristics</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" colspan="6" rowspan="1">Treated vessel</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Left main</td>
                      <td align="left" rowspan="1" colspan="1">0.0% (0/60)</td>
                      <td align="left" rowspan="1" colspan="1">0.0% (0/30)</td>
                      <td align="left" rowspan="1" colspan="1">5.0% (1/20)</td>
                      <td align="left" rowspan="1" colspan="1">1.3% (21/1658)</td>
                      <td align="left" rowspan="6" colspan="1">0.030</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">LAD</td>
                      <td align="left" rowspan="1" colspan="1">38.3% (23/60)</td>
                      <td align="left" rowspan="1" colspan="1">20.0% (6/30)</td>
                      <td align="left" rowspan="1" colspan="1">40.0% (8/20)</td>
                      <td align="left" rowspan="1" colspan="1">37.7% (625/1658)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">RCA</td>
                      <td align="left" rowspan="1" colspan="1">28.3% (17/60)</td>
                      <td align="left" rowspan="1" colspan="1">53.3% (16/30)</td>
                      <td align="left" rowspan="1" colspan="1">45.0% (9/20)</td>
                      <td align="left" rowspan="1" colspan="1">33.2% (550/1658)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Circumflex</td>
                      <td align="left" rowspan="1" colspan="1">23.3% (14/60)</td>
                      <td align="left" rowspan="1" colspan="1">26.7% (8/30)</td>
                      <td align="left" rowspan="1" colspan="1">10.0% (2/20)</td>
                      <td align="left" rowspan="1" colspan="1">23.4% (388/1658)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Venous graft</td>
                      <td align="left" rowspan="1" colspan="1">10.0% (6/60)</td>
                      <td align="left" rowspan="1" colspan="1">0.0% (0/30)</td>
                      <td align="left" rowspan="1" colspan="1">0.0% (0/20)</td>
                      <td align="left" rowspan="1" colspan="1">4.0% (66/1658)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Arterial graft</td>
                      <td align="left" rowspan="1" colspan="1">0.0% (0/60)</td>
                      <td align="left" rowspan="1" colspan="1">0.0% (0/30)</td>
                      <td align="left" rowspan="1" colspan="1">0.0% (0/20)</td>
                      <td align="left" rowspan="1" colspan="1">0.5% (8/1658)</td>
                    </tr>
                    <tr>
                      <td align="left" colspan="6" rowspan="1">DES types, identified at index (per patient)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Cypher</td>
                      <td align="left" rowspan="1" colspan="1">19.5% (8/41)</td>
                      <td align="left" rowspan="1" colspan="1">10.0% (2/20)</td>
                      <td align="left" rowspan="1" colspan="1">21.4% (3/14)</td>
                      <td align="left" rowspan="1" colspan="1">12.8% (149/1160)</td>
                      <td align="left" rowspan="5" colspan="1">0.038</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Endeavor</td>
                      <td align="left" rowspan="1" colspan="1">14.6% (6/41)</td>
                      <td align="left" rowspan="1" colspan="1">5.0% (1/20)</td>
                      <td align="left" rowspan="1" colspan="1">14.3% (2/14)</td>
                      <td align="left" rowspan="1" colspan="1">14.4% (167/1160)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">TAXUS</td>
                      <td align="left" rowspan="1" colspan="1">24.4% (10/41)</td>
                      <td align="left" rowspan="1" colspan="1">0.0% (0/20)</td>
                      <td align="left" rowspan="1" colspan="1">21.4% (3/14)</td>
                      <td align="left" rowspan="1" colspan="1">20.3% (236/1160)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Xience/PROMUS</td>
                      <td align="left" rowspan="1" colspan="1">41.5% (17/41)</td>
                      <td align="left" rowspan="1" colspan="1">85.0% (17/20)</td>
                      <td align="left" rowspan="1" colspan="1">42.9% (6/14)</td>
                      <td align="left" rowspan="1" colspan="1">50.2% (582/1160)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">&gt;1 DES type</td>
                      <td align="left" rowspan="1" colspan="1">0.0% (0/41)</td>
                      <td align="left" rowspan="1" colspan="1">0.0% (0/20)</td>
                      <td align="left" rowspan="1" colspan="1">0.0% (0/14)</td>
                      <td align="left" rowspan="1" colspan="1">2.2% (26/1160)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" colspan="6" rowspan="1">Minimum stent diameter (per patient)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">&lt;3</td>
                      <td align="left" rowspan="1" colspan="1">48.9% (23/47)</td>
                      <td align="left" rowspan="1" colspan="1">70.8% (17/24)</td>
                      <td align="left" rowspan="1" colspan="1">40.0% (6/15)</td>
                      <td align="left" rowspan="1" colspan="1">48.1% (601/1250)</td>
                      <td align="left" rowspan="2" colspan="1">0.113</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">≥3</td>
                      <td align="left" rowspan="1" colspan="1">51.1% (24/47)</td>
                      <td align="left" rowspan="1" colspan="1">29.2% (7/24)</td>
                      <td align="left" rowspan="1" colspan="1">60.0% (9/15)</td>
                      <td align="left" rowspan="1" colspan="1">51.9% (649/1250)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" colspan="6" rowspan="1">Total stent lengths, mm (sum per patient)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Mean±SD, n</td>
                      <td align="left" rowspan="1" colspan="1">27.1±16.0 (47)</td>
                      <td align="left" rowspan="1" colspan="1">27.1±15.2 (24)</td>
                      <td align="left" rowspan="1" colspan="1">25.3±16.6 (15)</td>
                      <td align="left" rowspan="1" colspan="1">26.2±16.2 (1250)</td>
                      <td align="left" rowspan="3" colspan="1">0.917</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Median (Q1, Q3)</td>
                      <td align="left" rowspan="1" colspan="1">20.0 (16.0, 32.0)</td>
                      <td align="left" rowspan="1" colspan="1">25.0 (15.0, 39.0)</td>
                      <td align="left" rowspan="1" colspan="1">24.0 (12.0, 32.0)</td>
                      <td align="left" rowspan="1" colspan="1">23.0 (15.0, 30.0)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Range (min, max)</td>
                      <td align="left" rowspan="1" colspan="1">(8.0, 85.0)</td>
                      <td align="left" rowspan="1" colspan="1">(8.0, 56.0)</td>
                      <td align="left" rowspan="1" colspan="1">(8.0, 74.0)</td>
                      <td align="left" rowspan="1" colspan="1">(8.0, 140.0)</td>
                    </tr>
                    <tr>
                      <td align="left" colspan="6" rowspan="1">Randomization group</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Placebo</td>
                      <td align="left" rowspan="1" colspan="1">61.7% (29/47)</td>
                      <td align="left" rowspan="1" colspan="1">54.2% (13/24)</td>
                      <td align="left" rowspan="1" colspan="1">53.3% (8/15)</td>
                      <td align="left" rowspan="1" colspan="1">50.2% (628/1250)</td>
                      <td align="left" rowspan="2" colspan="1">0.762</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Continued thienopyridine</td>
                      <td align="left" rowspan="1" colspan="1">38.3% (18/47)</td>
                      <td align="left" rowspan="1" colspan="1">45.8% (11/24)</td>
                      <td align="left" rowspan="1" colspan="1">46.7% (7/15)</td>
                      <td align="left" rowspan="1" colspan="1">49.8% (622/1250)</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot id="jah36005-ntgp-0002">
                  <fn id="jah36005-note-0002">
                    <p>STEMI indicates ST‐segment‒elevation myocardial infarction; NSTEMI, non‒ST‐segment‒elevation myocardial infarction; LAD, left anterior descending; RCA, right coronary artery; and DES, drug‐eluting stent.</p>
                  </fn>
                  <fn id="jah36005-note-0003">
                    <label>*</label>
                    <p>Between‐group differences were assessed using an ANOVA test for continuous variables or a Fisher exact test for categorical variables comparing first 3 columns only (no event column not included).</p>
                  </fn>
                </table-wrap-foot>
                <permissions>
                  <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
                </permissions>
              </table-wrap>
              <table-wrap id="jah36005-tbl-0002" xml:lang="en" content-type="Table" orientation="portrait" position="float">
                <label>Table 2</label>
                <caption>
                  <p>Baseline Characteristics of Patients With Bleeding Events in Trials and Claims Data</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <thead valign="top">
                    <tr style="border-bottom:solid 1px #000000">
                      <th align="left" valign="top" rowspan="1" colspan="1">Characteristics</th>
                      <th align="left" valign="top" rowspan="1" colspan="1">Event in Both Trial and Claims (n=44)</th>
                      <th align="left" valign="top" rowspan="1" colspan="1">Event in Trial Only (n=13)</th>
                      <th align="left" valign="top" rowspan="1" colspan="1">Event in Claims Only (n=65)</th>
                      <th align="left" valign="top" rowspan="1" colspan="1">No Event (n=1214)</th>
                      <th align="left" valign="top" rowspan="1" colspan="1"><italic>P</italic> Value<xref ref-type="fn" rid="jah36005-note-0005">*</xref>
</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td align="left" colspan="6" rowspan="1">Clinical characteristics</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" colspan="6" rowspan="1">Age, y</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Mean±SD, n</td>
                      <td align="left" rowspan="1" colspan="1">74.4±6.4 (44)</td>
                      <td align="left" rowspan="1" colspan="1">74.4±6.4 (13)</td>
                      <td align="left" rowspan="1" colspan="1">73.5±5.4 (65)</td>
                      <td align="left" rowspan="1" colspan="1">71.6±5.4 (1214)</td>
                      <td align="left" rowspan="3" colspan="1">0.728</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Median (Q1, Q3)</td>
                      <td align="left" rowspan="1" colspan="1">73.0 (70.0, 80.5)</td>
                      <td align="left" rowspan="1" colspan="1">74.0 (70.0, 80.0)</td>
                      <td align="left" rowspan="1" colspan="1">72.0 (70.0, 76.0)</td>
                      <td align="left" rowspan="1" colspan="1">70.0 (67.0, 75.0)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Range (min, max)</td>
                      <td align="left" rowspan="1" colspan="1">(65.0, 87.0)</td>
                      <td align="left" rowspan="1" colspan="1">(66.0, 85.0)</td>
                      <td align="left" rowspan="1" colspan="1">(65.0, 89.0)</td>
                      <td align="left" rowspan="1" colspan="1">(65.0, 91.0)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Women</td>
                      <td align="left" rowspan="1" colspan="1">38.6% (17/44)</td>
                      <td align="left" rowspan="1" colspan="1">30.8% (4/13)</td>
                      <td align="left" rowspan="1" colspan="1">43.1% (28/65)</td>
                      <td align="left" rowspan="1" colspan="1">32.0% (388/1214)</td>
                      <td align="left" rowspan="1" colspan="1">0.717</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" colspan="6" rowspan="1">Race</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">American Indian or Alaska Native</td>
                      <td align="left" rowspan="1" colspan="1">0.0% (0/44)</td>
                      <td align="left" rowspan="1" colspan="1">0.0% (0/13)</td>
                      <td align="left" rowspan="1" colspan="1">0.0% (0/65)</td>
                      <td align="left" rowspan="1" colspan="1">0.2% (3/1208)</td>
                      <td align="left" rowspan="6" colspan="1">0.210</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Asian</td>
                      <td align="left" rowspan="1" colspan="1">0.0% (0/44)</td>
                      <td align="left" rowspan="1" colspan="1">7.7% (1/13)</td>
                      <td align="left" rowspan="1" colspan="1">0.0% (0/65)</td>
                      <td align="left" rowspan="1" colspan="1">0.6% (7/1208)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Black</td>
                      <td align="left" rowspan="1" colspan="1">4.5% (2/44)</td>
                      <td align="left" rowspan="1" colspan="1">7.7% (1/13)</td>
                      <td align="left" rowspan="1" colspan="1">3.1% (2/65)</td>
                      <td align="left" rowspan="1" colspan="1">3.8% (46/1208)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Native Hawaiian or Other Pacific Islander</td>
                      <td align="left" rowspan="1" colspan="1">2.3% (1/44)</td>
                      <td align="left" rowspan="1" colspan="1">0.0% (0/13)</td>
                      <td align="left" rowspan="1" colspan="1">0.0% (0/65)</td>
                      <td align="left" rowspan="1" colspan="1">0.1% (1/1208)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">White</td>
                      <td align="left" rowspan="1" colspan="1">88.6% (39/44)</td>
                      <td align="left" rowspan="1" colspan="1">84.6% (11/13)</td>
                      <td align="left" rowspan="1" colspan="1">95.4% (62/65)</td>
                      <td align="left" rowspan="1" colspan="1">93.5% (1130/1208)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Other</td>
                      <td align="left" rowspan="1" colspan="1">4.5% (2/44)</td>
                      <td align="left" rowspan="1" colspan="1">0.0% (0/13)</td>
                      <td align="left" rowspan="1" colspan="1">1.5% (1/65)</td>
                      <td align="left" rowspan="1" colspan="1">1.7% (21/1208)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hispanic or Latino</td>
                      <td align="left" rowspan="1" colspan="1">4.7% (2/43)</td>
                      <td align="left" rowspan="1" colspan="1">0.0% (0/13)</td>
                      <td align="left" rowspan="1" colspan="1">1.5% (1/65)</td>
                      <td align="left" rowspan="1" colspan="1">2.5% (30/1209)</td>
                      <td align="left" rowspan="1" colspan="1">0.689</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" colspan="6" rowspan="1">Body mass index, Kg/m<sup>2</sup>
</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Mean±SD, n</td>
                      <td align="left" rowspan="1" colspan="1">28.5±5.3 (44)</td>
                      <td align="left" rowspan="1" colspan="1">29.2±4.6 (13)</td>
                      <td align="left" rowspan="1" colspan="1">29.6±5.5 (65)</td>
                      <td align="left" rowspan="1" colspan="1">29.7±5.3 (1214)</td>
                      <td align="left" rowspan="3" colspan="1">0.538</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Median (Q1, Q3)</td>
                      <td align="left" rowspan="1" colspan="1">27.3 (24.6, 31.1)</td>
                      <td align="left" rowspan="1" colspan="1">29.0 (27.0, 31.7)</td>
                      <td align="left" rowspan="1" colspan="1">29.0 (26.1, 31.6)</td>
                      <td align="left" rowspan="1" colspan="1">29.0 (26.0, 32.5)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Range (min, max)</td>
                      <td align="left" rowspan="1" colspan="1">(19.3, 44.7)</td>
                      <td align="left" rowspan="1" colspan="1">(21.1, 36.1)</td>
                      <td align="left" rowspan="1" colspan="1">(19.0, 47.0)</td>
                      <td align="left" rowspan="1" colspan="1">(15.7, 52.2)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Diabetes mellitus</td>
                      <td align="left" rowspan="1" colspan="1">32.6% (14/43)</td>
                      <td align="left" rowspan="1" colspan="1">38.5% (5/13)</td>
                      <td align="left" rowspan="1" colspan="1">46.2% (30/65)</td>
                      <td align="left" rowspan="1" colspan="1">32.5% (394/1213)</td>
                      <td align="left" rowspan="1" colspan="1">0.366</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Insulin</td>
                      <td align="left" rowspan="1" colspan="1">4.7% (2/43)</td>
                      <td align="left" rowspan="1" colspan="1">7.7% (1/13)</td>
                      <td align="left" rowspan="1" colspan="1">12.3% (8/65)</td>
                      <td align="left" rowspan="1" colspan="1">8.5% (103/1213)</td>
                      <td align="left" rowspan="1" colspan="1">0.425</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Oral medications</td>
                      <td align="left" rowspan="1" colspan="1">25.6% (11/43)</td>
                      <td align="left" rowspan="1" colspan="1">30.8% (4/13)</td>
                      <td align="left" rowspan="1" colspan="1">30.8% (20/65)</td>
                      <td align="left" rowspan="1" colspan="1">20.1% (244/1213)</td>
                      <td align="left" rowspan="1" colspan="1">0.840</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Diet controlled or no treatment</td>
                      <td align="left" rowspan="1" colspan="1">2.3% (1/43)</td>
                      <td align="left" rowspan="1" colspan="1">0.0% (0/13)</td>
                      <td align="left" rowspan="1" colspan="1">3.1% (2/65)</td>
                      <td align="left" rowspan="1" colspan="1">3.9% (47/1213)</td>
                      <td align="left" rowspan="1" colspan="1">1.000</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hypertension</td>
                      <td align="left" rowspan="1" colspan="1">81.8% (36/44)</td>
                      <td align="left" rowspan="1" colspan="1">92.3% (12/13)</td>
                      <td align="left" rowspan="1" colspan="1">86.2% (56/65)</td>
                      <td align="left" rowspan="1" colspan="1">85.1% (1030/1210)</td>
                      <td align="left" rowspan="1" colspan="1">0.705</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Peripheral artery disease</td>
                      <td align="left" rowspan="1" colspan="1">18.6% (8/43)</td>
                      <td align="left" rowspan="1" colspan="1">15.4% (2/13)</td>
                      <td align="left" rowspan="1" colspan="1">15.6% (10/64)</td>
                      <td align="left" rowspan="1" colspan="1">9.8% (117/1197)</td>
                      <td align="left" rowspan="1" colspan="1">0.937</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Congestive heart failure</td>
                      <td align="left" rowspan="1" colspan="1">9.1% (4/44)</td>
                      <td align="left" rowspan="1" colspan="1">7.7% (1/13)</td>
                      <td align="left" rowspan="1" colspan="1">10.9% (7/64)</td>
                      <td align="left" rowspan="1" colspan="1">6.1% (73/1206)</td>
                      <td align="left" rowspan="1" colspan="1">1.000</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Previous myocardial infarction</td>
                      <td align="left" rowspan="1" colspan="1">19.0% (8/42)</td>
                      <td align="left" rowspan="1" colspan="1">23.1% (3/13)</td>
                      <td align="left" rowspan="1" colspan="1">19.7% (12/61)</td>
                      <td align="left" rowspan="1" colspan="1">21.1% (250/1184)</td>
                      <td align="left" rowspan="1" colspan="1">0.893</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Stroke/Transient ischemic attack</td>
                      <td align="left" rowspan="1" colspan="1">7.0% (3/43)</td>
                      <td align="left" rowspan="1" colspan="1">7.7% (1/13)</td>
                      <td align="left" rowspan="1" colspan="1">6.2% (4/65)</td>
                      <td align="left" rowspan="1" colspan="1">5.3% (64/1212)</td>
                      <td align="left" rowspan="1" colspan="1">1.000</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" colspan="6" rowspan="1">Prior procedures</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Previous percutaneous coronary intervention</td>
                      <td align="left" rowspan="1" colspan="1">40.9% (18/44)</td>
                      <td align="left" rowspan="1" colspan="1">30.8% (4/13)</td>
                      <td align="left" rowspan="1" colspan="1">43.8% (28/64)</td>
                      <td align="left" rowspan="1" colspan="1">34.6% (418/1207)</td>
                      <td align="left" rowspan="1" colspan="1">0.745</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Coronary artery bypass graft</td>
                      <td align="left" rowspan="1" colspan="1">18.2% (8/44)</td>
                      <td align="left" rowspan="1" colspan="1">23.1% (3/13)</td>
                      <td align="left" rowspan="1" colspan="1">18.5% (12/65)</td>
                      <td align="left" rowspan="1" colspan="1">16.3% (198/1212)</td>
                      <td align="left" rowspan="1" colspan="1">0.890</td>
                    </tr>
                    <tr>
                      <td align="left" colspan="6" rowspan="1">Indication for index procedure</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Acute coronary syndrome</td>
                      <td align="left" rowspan="1" colspan="1">15.9% (7/44)</td>
                      <td align="left" rowspan="1" colspan="1">23.1% (3/13)</td>
                      <td align="left" rowspan="1" colspan="1">9.2% (6/65)</td>
                      <td align="left" rowspan="1" colspan="1">15.3% (186/1214)</td>
                      <td align="left" rowspan="1" colspan="1">0.263</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">STEMI</td>
                      <td align="left" rowspan="1" colspan="1">6.8% (3/44)</td>
                      <td align="left" rowspan="1" colspan="1">0.0% (0/13)</td>
                      <td align="left" rowspan="1" colspan="1">4.6% (3/65)</td>
                      <td align="left" rowspan="1" colspan="1">3.9% (47/1214)</td>
                      <td align="left" rowspan="1" colspan="1">0.842</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">NSTEMI</td>
                      <td align="left" rowspan="1" colspan="1">9.1% (4/44)</td>
                      <td align="left" rowspan="1" colspan="1">23.1% (3/13)</td>
                      <td align="left" rowspan="1" colspan="1">4.6% (3/65)</td>
                      <td align="left" rowspan="1" colspan="1">11.4% (139/1214)</td>
                      <td align="left" rowspan="1" colspan="1">0.090</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Unstable angina<sup>3</sup>
</td>
                      <td align="left" rowspan="1" colspan="1">13.6% (6/44)</td>
                      <td align="left" rowspan="1" colspan="1">7.7% (1/13)</td>
                      <td align="left" rowspan="1" colspan="1">7.7% (5/65)</td>
                      <td align="left" rowspan="1" colspan="1">15.6% (189/1214)</td>
                      <td align="left" rowspan="1" colspan="1">0.681</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Stable angina</td>
                      <td align="left" rowspan="1" colspan="1">43.2% (19/44)</td>
                      <td align="left" rowspan="1" colspan="1">15.4% (2/13)</td>
                      <td align="left" rowspan="1" colspan="1">52.3% (34/65)</td>
                      <td align="left" rowspan="1" colspan="1">45.1% (547/1214)</td>
                      <td align="left" rowspan="1" colspan="1">0.046</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Other</td>
                      <td align="left" rowspan="1" colspan="1">27.3% (12/44)</td>
                      <td align="left" rowspan="1" colspan="1">53.8% (7/13)</td>
                      <td align="left" rowspan="1" colspan="1">30.8% (20/65)</td>
                      <td align="left" rowspan="1" colspan="1">24.1% (292/1214)</td>
                      <td align="left" rowspan="1" colspan="1">0.206</td>
                    </tr>
                    <tr>
                      <td align="left" colspan="6" rowspan="1">Procedural characteristics</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" colspan="6" rowspan="1">Treated vessel</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Left main</td>
                      <td align="left" rowspan="1" colspan="1">0.0% (0/63)</td>
                      <td align="left" rowspan="1" colspan="1">0.0% (0/21)</td>
                      <td align="left" rowspan="1" colspan="1">1.3% (1/80)</td>
                      <td align="left" rowspan="1" colspan="1">1.3% (21/1604)</td>
                      <td align="left" rowspan="6" colspan="1">0.032</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">LAD</td>
                      <td align="left" rowspan="1" colspan="1">33.3% (21/63)</td>
                      <td align="left" rowspan="1" colspan="1">23.8% (5/21)</td>
                      <td align="left" rowspan="1" colspan="1">52.5% (42/80)</td>
                      <td align="left" rowspan="1" colspan="1">37.0% (594/1604)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">RCA</td>
                      <td align="left" rowspan="1" colspan="1">23.8% (15/63)</td>
                      <td align="left" rowspan="1" colspan="1">52.4% (11/21)</td>
                      <td align="left" rowspan="1" colspan="1">26.3% (21/80)</td>
                      <td align="left" rowspan="1" colspan="1">34.0% (545/1604)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Circumflex</td>
                      <td align="left" rowspan="1" colspan="1">33.3% (21/63)</td>
                      <td align="left" rowspan="1" colspan="1">19.0% (4/21)</td>
                      <td align="left" rowspan="1" colspan="1">15.0% (12/80)</td>
                      <td align="left" rowspan="1" colspan="1">23.4% (375/1604)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Venous graft</td>
                      <td align="left" rowspan="1" colspan="1">7.9% (5/63)</td>
                      <td align="left" rowspan="1" colspan="1">0.0% (0/21)</td>
                      <td align="left" rowspan="1" colspan="1">3.8% (3/80)</td>
                      <td align="left" rowspan="1" colspan="1">4.0% (64/1604)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Arterial graft</td>
                      <td align="left" rowspan="1" colspan="1">1.6% (1/63)</td>
                      <td align="left" rowspan="1" colspan="1">4.8% (1/21)</td>
                      <td align="left" rowspan="1" colspan="1">1.3% (1/80)</td>
                      <td align="left" rowspan="1" colspan="1">0.3% (5/1604)</td>
                    </tr>
                    <tr>
                      <td align="left" colspan="6" rowspan="1">DES types, identified at index (per patient)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Cypher</td>
                      <td align="left" rowspan="1" colspan="1">12.2% (5/41)</td>
                      <td align="left" rowspan="1" colspan="1">23.1% (3/13)</td>
                      <td align="left" rowspan="1" colspan="1">15.3% (9/59)</td>
                      <td align="left" rowspan="1" colspan="1">12.9% (145/1122)</td>
                      <td align="left" rowspan="5" colspan="1">0.613</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Endeavor</td>
                      <td align="left" rowspan="1" colspan="1">12.2% (5/41)</td>
                      <td align="left" rowspan="1" colspan="1">7.7% (1/13)</td>
                      <td align="left" rowspan="1" colspan="1">10.2% (6/59)</td>
                      <td align="left" rowspan="1" colspan="1">14.6% (164/1122)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">TAXUS</td>
                      <td align="left" rowspan="1" colspan="1">22.0% (9/41)</td>
                      <td align="left" rowspan="1" colspan="1">7.7% (1/13)</td>
                      <td align="left" rowspan="1" colspan="1">25.4% (15/59)</td>
                      <td align="left" rowspan="1" colspan="1">20.0% (224/1122)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Xience/PROMUS</td>
                      <td align="left" rowspan="1" colspan="1">51.2% (21/41)</td>
                      <td align="left" rowspan="1" colspan="1">53.8% (7/13)</td>
                      <td align="left" rowspan="1" colspan="1">49.2% (29/59)</td>
                      <td align="left" rowspan="1" colspan="1">50.4% (565/1122)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">&gt;1 DES type</td>
                      <td align="left" rowspan="1" colspan="1">2.4% (1/41)</td>
                      <td align="left" rowspan="1" colspan="1">7.7% (1/13)</td>
                      <td align="left" rowspan="1" colspan="1">0.0% (0/59)</td>
                      <td align="left" rowspan="1" colspan="1">2.1% (24/1122)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" colspan="6" rowspan="1">Minimum stent diameter (per patient)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">&lt;3</td>
                      <td align="left" rowspan="1" colspan="1">40.9% (18/44)</td>
                      <td align="left" rowspan="1" colspan="1">46.2% (6/13)</td>
                      <td align="left" rowspan="1" colspan="1">52.3% (34/65)</td>
                      <td align="left" rowspan="1" colspan="1">48.5% (589/1214)</td>
                      <td align="left" rowspan="2" colspan="1">0.509</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">≥3</td>
                      <td align="left" rowspan="1" colspan="1">59.1% (26/44)</td>
                      <td align="left" rowspan="1" colspan="1">53.8% (7/13)</td>
                      <td align="left" rowspan="1" colspan="1">47.7% (31/65)</td>
                      <td align="left" rowspan="1" colspan="1">51.5% (625/1214)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" colspan="6" rowspan="1">Total stent lengths, mm (sum per patient)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Mean±SD, n</td>
                      <td align="left" rowspan="1" colspan="1">28.9±20.4 (44)</td>
                      <td align="left" rowspan="1" colspan="1">28.8±16.4 (13)</td>
                      <td align="left" rowspan="1" colspan="1">22.8±12.0 (65)</td>
                      <td align="left" rowspan="1" colspan="1">26.3±16.2 (1214)</td>
                      <td align="left" rowspan="3" colspan="1">0.113</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Median (Q1, Q3)</td>
                      <td align="left" rowspan="1" colspan="1">22.5 (16.5, 29.0)</td>
                      <td align="left" rowspan="1" colspan="1">28.0 (15.0, 41.0)</td>
                      <td align="left" rowspan="1" colspan="1">18.0 (15.0, 28.0)</td>
                      <td align="left" rowspan="1" colspan="1">23.0 (15.0, 31.0)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Range (min, max)</td>
                      <td align="left" rowspan="1" colspan="1">(8.0, 99.0)</td>
                      <td align="left" rowspan="1" colspan="1">(8.0, 61.0)</td>
                      <td align="left" rowspan="1" colspan="1">(8.0, 80.0)</td>
                      <td align="left" rowspan="1" colspan="1">(8.0, 140.0)</td>
                    </tr>
                    <tr>
                      <td align="left" colspan="6" rowspan="1">Randomization group</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Placebo</td>
                      <td align="left" rowspan="1" colspan="1">45.5% (20/44)</td>
                      <td align="left" rowspan="1" colspan="1">30.8% (4/13)</td>
                      <td align="left" rowspan="1" colspan="1">41.5% (27/65)</td>
                      <td align="left" rowspan="1" colspan="1">51.6% (627/1214)</td>
                      <td align="left" rowspan="2" colspan="1">0.695</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Continued thienopyridine</td>
                      <td align="left" rowspan="1" colspan="1">54.5% (24/44)</td>
                      <td align="left" rowspan="1" colspan="1">69.2% (9/13)</td>
                      <td align="left" rowspan="1" colspan="1">58.5% (38/65)</td>
                      <td align="left" rowspan="1" colspan="1">48.4% (587/1214)</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot id="jah36005-ntgp-0003">
                  <fn id="jah36005-note-0004">
                    <p>STEMI indicates ST‐segment‒elevation myocardial infarction; NSTEMI, non‒ST‐segment‒elevation myocardial infarction; LAD, left anterior descending; RCA, right coronary artery; and DES, drug‐eluting stent.</p>
                  </fn>
                  <fn id="jah36005-note-0005">
                    <label>*</label>
                    <p>Between‐group differences were assessed using an ANOVA test for continuous variables or a Fisher exact test for categorical variables comparing first 3 columns only (no event column not included).</p>
                  </fn>
                </table-wrap-foot>
                <permissions>
                  <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
                </permissions>
              </table-wrap>
              <p>The unadjusted annualized mortality rate after an ischemic event identified with both trial adjudication and claims, an ischemic event identified with trial adjudication only, an ischemic event identified with claims only, and among those without an ischemic event was 12.8, 5.5, 14.9, and 1.26 per 100 person‐years, respectively (Figure <xref rid="jah36005-fig-0001" ref-type="fig">1A</xref>). The unadjusted annualized mortality rate after a bleeding event identified with both trial adjudication and claims, a bleeding event identified with trial adjudication only, a bleeding event identified with claims only, and among those without a bleeding event was 11.0, 16.8, 10.7, and 0.95 per 100 person‐years, respectively (Figure <xref rid="jah36005-fig-0001" ref-type="fig">1B</xref>).</p>
              <p>The adjusted HRs for mortality following an ischemic event were 21.5 (95% CI, 9.1–50.4) when identified with both trial adjudication and claims, 9.5 (95% CI, 2.2–40.9) when identified with trial adjudication only, and 31.5 (95% CI, 8.9–111.9) when identified with claims only, relative to those who did not have an event (Figure <xref rid="jah36005-fig-0002" ref-type="fig">2A</xref>). Although CIs for point estimates were wide, the lower bound of the CIs in each group did not cross 1. There was no significant difference in the mortality HR in pair‐wise comparisons across these 3 groups.</p>
              <fig fig-type="Figure" xml:lang="en" id="jah36005-fig-0002" orientation="portrait" position="float">
                <label>Figure 2</label>
                <caption>
                  <title>Adjusted risk of mortality after trial vs claims‐based ischemic or bleeding events during the 21‐month post‐randomization period.</title>
                  <p>(<bold>A</bold>) Ischemic events; <bold>(B</bold>) Bleeding events. Hazard ratios compare risk of death of patients with clinical events relative to those without such events. Models are adjusted for predicted probability of having ischemic or bleeding events at 21 months based on models from the DAPT (Dual Antiplatelet Therapy) study. The DAPT study ischemic risk model includes whether a patient had a myocardial infarction at presentation, prior percutaneous coronary intervention or MI, history of heart failure or left ventricular ejection fraction &lt;30%, vein graft percutaneous coronary intervention, stent diameter &lt;3 mm, use of a paclitaxel‐eluting stent, smoking status, diabetes mellitus, peripheral artery disease, hypertension, and renal insufficiency. The DAPT study bleeding risk model includes age, peripheral artery disease, hypertension, and renal insufficiency. For ischemic events, pairwise <italic>P</italic> value comparing both trial and claims vs trial only, 0.304; pairwise <italic>P</italic> value comparing both trial and claims vs claims only, 0.576; and pairwise <italic>P</italic> value comparing trial only vs claims only, 0.193, based on the Wald test. Global Chi‐squared statistic comparing all ischemic event 3 groups, 2.861; and <italic>P</italic> value from Wald test comparing all 3 groups, 0.239. For bleeding events, pairwise <italic>P</italic> value comparing both trial and claims vs trial only, 0.145; pairwise <italic>P</italic> value comparing both trial and claims vs claims only, 0.545; and pairwise <italic>P</italic> value comparing trial only vs claims only, 0.283 based on the Wald test. Global Chi‐squared statistic comparing all 3 bleeding event groups, 2.878; and <italic>P</italic> value from Wald test comparing all 3 groups, 0.237.</p>
                </caption>
                <graphic id="jats-graphic-3" xlink:href="JAH3-10-e018744-g001"/>
              </fig>
              <p>The adjusted HRs for mortality following a bleeding event were 17.7 (95% CI, 7.0–44.8) when identified with trial adjudication and claims, 48.7 (95% CI, 13.6–73.6) when identified with trial adjudication only, and 23.9 (95% CI, 10.7–53.2) when identified with claims only, relative to those who did not have an event (Figure <xref rid="jah36005-fig-0002" ref-type="fig">2B</xref>). Once again, although CIs for point estimates were wide, the lower bound of the CIs in each group did not cross 1. Again, there was no significant difference in the mortality HR in pair‐wise comparisons across these 3 groups.</p>
              <p>In supplemental analysis, the unadjusted annualized mortality rate after any ischemic event identified via trial adjudication (n=71) was 10.1 person‐years (95% CI, 5.4‒18.8) and the unadjusted annualized mortality rate after any ischemic event identified via claims (n=62) was 5.5 person‐years (95% CI, 1.4‒22.0; Table <xref rid="jah36005-sup-0001" ref-type="supplementary-material">S3</xref>). Additionally, the unadjusted annualized mortality rate after any bleeding event identified via trial adjudication (n=57) was 12.3 person‐years (95% CI, 6.6‒22.8) and the unadjusted annualized mortality rate after any ischemic event identified via claims (n=109) was 10.8 person‐years (95% CI, 6.7‒71.4).</p>
            </sec>
            <sec sec-type="discussion" id="jah36005-sec-0015">
              <title>DISCUSSION</title>
              <p>This study examined the prognosis of claims‐based versus trial‐based clinical events in the DAPT study. We found that, in addition to trial‐adjudicated events, ischemic and bleeding events ascertained using claims were prognostically significant for death. These results demonstrate the incremental value of claims in identifying additional clinically meaningful outcomes in future cardiovascular clinical trials.</p>
              <p>This study extends prior knowledge on prognosis of ischemic and bleeding events post‐PCI. Previous studies have evaluated the relationship between post‐PCI clinical events and mortality with differing definitions of end points and duration of follow‐up. In the CHAMPION‐PHEONIX trial, both centrally Clinical Events Committee‐adjudicated MI and site investigator‐identified MI had independent prognostic significance for higher 30‐day death.<xref rid="jah36005-bib-0024" ref-type="ref"><sup>24</sup></xref> Ischemic and bleeding events ascertained from electronic health records have also previously been demonstrated to identify patients with poor prognosis in the first year after PCI.<xref rid="jah36005-bib-0010" ref-type="ref"><sup>10</sup></xref> Additionally, trial‐adjudicated bleeding events have been associated with worse outcomes up to 1 year,<xref rid="jah36005-bib-0025" ref-type="ref"><sup>25</sup></xref> and registry‐based ascertainment of bleeding events was associated with increased risk of death up to 2 years post‐PCI.<xref rid="jah36005-bib-0011" ref-type="ref"><sup>11</sup></xref>, <xref rid="jah36005-bib-0026" ref-type="ref"><sup>26</sup></xref> A sub‐analysis of the DAPT study found that both trial‐adjudicated ischemic and bleeding events beyond 1 year and up to 30 months post‐PCI were associated with worse mortality.<xref rid="jah36005-bib-0012" ref-type="ref"><sup>12</sup></xref> However, there are limited data on the prognostic impact of clinical events that may not meet strict criteria for trial adjudication at this interval. We found that ischemic and bleeding events identified only via administrative claims have a similar prognosis for death as trial‐adjudicated events beyond 1 year after PCI, despite controlling for baseline ischemic or bleeding risk. These results suggest that ischemic and bleeding events continue to have poor prognostic impact beyond 1 year after PCI, irrespective of clinical event definition or ascertainment mechanism.</p>
              <p>The results from this study demonstrate the potential value of claims‐based approaches to ascertain additional clinically meaningful events in clinical trials. Some have suggested that using claims to augment outcome ascertainment in clinical trials can improve the efficiency of clinical trial data collection.<xref rid="jah36005-bib-0004" ref-type="ref"><sup>4</sup></xref>, <xref rid="jah36005-bib-0005" ref-type="ref"><sup>5</sup></xref>, <xref rid="jah36005-bib-0006" ref-type="ref"><sup>6</sup></xref> However, studies evaluating the accuracy of claims in ascertaining clinically adjudicated outcomes in large observational studies have found discordant results.<xref rid="jah36005-bib-0020" ref-type="ref"><sup>20</sup></xref>, <xref rid="jah36005-bib-0027" ref-type="ref"><sup>27</sup></xref>, <xref rid="jah36005-bib-0028" ref-type="ref"><sup>28</sup></xref> An analysis of the DAPT study found that claims data had moderate agreement with trial‐adjudicated MI, but poor agreement for trial‐adjudicated bleeding and stroke.<xref rid="jah36005-bib-0015" ref-type="ref"><sup>15</sup></xref>, <xref rid="jah36005-bib-0017" ref-type="ref"><sup>17</sup></xref> Nevertheless, treatment effects of extended‐duration DAPT after PCI using claims‐derived events were numerically similar to those using adjudicated events.<xref rid="jah36005-bib-0017" ref-type="ref"><sup>17</sup></xref> Discrepancies between trial‐ and claims‐based events may stem from differences between the stringent trial end point definitions and the broad inclusion criteria in claims‐based approaches, particular for softer end points. However, these additional claims‐based events were not simply mild events not meeting the adjudication threshold, as the vast majority of claims‐only bleeding events were also not captured as lesser severity Bleeding Academic Research Consortium Type 2 events in the trial. We find that instances in which claims and trials are discordant in identifying a clinical event are still clinically meaningful for patient mortality after PCI. Thus, claims may help identify additional patients with ischemic and bleeding events with important prognostic implications post‐PCI that would have otherwise not been captured in traditional trial adjudication. Future trials can incorporate authorization for linkage to insurance data prospectively using direct identifiers to identify such events in claims, and this can serve as an adjunct to existing trial adjudication processes. Future studies are needed to determine the prognosis of other claims‐based end points for their potential to augment cardiovascular clinical trials in other contexts.</p>
              <p>This study has implications for use of real‐world data to ascertain outcomes in future cardiovascular clinical trial design. As has been seen with the additional events captured with centralized adjudication in clinical trials,<xref rid="jah36005-bib-0024" ref-type="ref"><sup>24</sup></xref> claims‐based end points can identify additional meaningful events beyond trial adjudication as well as patients with poor prognosis, both of which can inform the understanding of an intervention's broader long‐term effects. Thus, predetermined definitions in clinical trials may be missing key events that have important prognostic value. However, given that claims‐based end point ascertainment may not be as precise in identifying specific clinical events, it may be best suited to operate in parallel with traditional trial adjudication processes. A hybrid model in which claims‐based events can trigger further trial adjudication and review may enhance the efficiency of clinical trial event ascertainment. It is important to note that, while both trial‐adjudicated and claims‐based clinical events are clinically meaningful, events of both types may not be in the causal pathway of a particular intervention being studied. Subtle differences in definitions of clinical events can have different prognostic implications and trial results,<xref rid="jah36005-bib-0007" ref-type="ref"><sup>7</sup></xref>, <xref rid="jah36005-bib-0008" ref-type="ref"><sup>8</sup></xref>, <xref rid="jah36005-bib-0009" ref-type="ref"><sup>9</sup></xref> as in the case of the EXCEL (Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization) trial in which variations in definition of periprocedural MI can lead to differing conclusions.<xref rid="jah36005-bib-0029" ref-type="ref"><sup>29</sup></xref>, <xref rid="jah36005-bib-0030" ref-type="ref"><sup>30</sup></xref> As such, incorporation of claims into the case definition of any trial must align with the intended construct of the outcome meant to be tested in the trial hypothesis. Although no statistically significant differences were found between claims versus trial‐based definitions of events, this study was underpowered to detect some clinically meaningful differences. Future studies will be important to determine if claims capture clinically distinct phenotypes that may have different long‐term clinical prognoses for a given intervention.</p>
              <p>This study's findings must be interpreted in context of its limitations. First, our cohort included only a subset of the full DAPT study that could be linked to Medicare claims data, as a large number of DAPT study patients were aged &lt;65 years or enrolled outside of the United States. The results thus may not be generalizable to other claims data sets or populations. Second, the number of events in our study is small, leading to wide CIs for HR estimates. Finally, this study only used <italic>ICD‐9</italic> codes, and results may differ with <italic>International Classification of Diseases, Tenth Revision, Clinical Modification</italic> (<italic>ICD‐10</italic>) codes, although sensitivity of <italic>ICD‐9</italic> versus <italic>ICD‐10</italic> codes in ascertaining cardiovascular end points is generally similar,<xref rid="jah36005-bib-0031" ref-type="ref"><sup>31</sup></xref> and most of the specific codes for MI and bleeding diagnoses across classification schemes are the same. Future research should investigate the prognostic significance of <italic>ICD‐10</italic> codes for ascertaining events.</p>
              <p>In examining patients in the DAPT study linked to administrative claims data, we found that clinical events identified with claims data had a prognostic impact similar to clinical events identified via trial adjudication. These results demonstrate the incremental value of claims‐based end points in identifying additional clinically meaningful events for subsequent adjudication and support the use of claims to augment clinical trial end point ascertainment in future cardiovascular clinical trials. Future studies will be important to determine the prognosis of other claims‐based end points and whether claims capture clinically distinct phenotypes that may have different implications for a given intervention in other contexts.</p>
            </sec>
            <sec id="jah36005-sec-0016">
              <title>Sources of Funding</title>
              <p>This research was supported by the National Heart, Lung, and Blood Institute (1R01HL136708) and the American College of Cardiology's NCDR. The views expressed in this article represent those of the authors, and do not necessarily represent the official views of the NCDR or its associated professional societies identified at CVQuality.ACC.org/NCDR.</p>
            </sec>
            <sec sec-type="COI-statement" id="jah36005-sec-0017">
              <title>Disclosures</title>
              <p>Dr. Butala is funded by the John S. LaDue Memorial Fellowship at Harvard Medical School, Boston, MA, and reports consulting fees and ownership interest in HiLabs, outside the submitted work. Dr. Secemsky receives grants from AstraZeneca, BD Bard, Boston Scientific, Cook Medical, CSI, Medtronic, Philips, and UCSF. He consults for BD Bard, CSI, Medtronic, and Philips and is on the speaking bureau of BD Bard, Cook Medical, and Medtronic. Dr. Curtis receives salary support under contracts with the American College of Cardiology and Centers for Medicare and Medicaid Services. Dr. Gibson reports grants and personal fees from Angel Medical Corporation, grants and personal fees from Bayer Corporation, grants and personal fees from CSL Behring, grants and personal fees from Janssen Pharmaceuticals, grants and personal fees from Johnson &amp; Johnson Corporation, personal fees from The Medicines Company, personal fees from Boston Clinical Research Institute, personal fees from Cardiovascular Research Foundation, personal fees from Eli Lilly and Company, personal fees from Gilead Sciences, Inc., personal fees from Novo Nordisk, personal fees from Web MD, personal fees from UpToDate in Cardiovascular Medicine, and grants and personal fees from Portola Pharmaceuticals. Dr Gibson also reports personal fees from Amarin Pharma, Amgen, Boehringer Ingelheim, Chiesi, Merck &amp; Co, Inc., PharmaMar, Sanofi, Somahlution, St. Francis Hospital, Verreseon Corporation, Boston Scientific, Duke Clinical Research Institute, Impact Bio, LTD, MedImmune, Medtelligence, Microport, PERT Consortium; other from nference; non‐financial support from Baim Institute; grants from Bristol‐Myers Squibb; grants from SCAD Alliance; personal fees from GE Healthcare, Caladrius Bioscience, CeleCor Therapeutics, Thrombolytic Science, AstraZeneca, Eidos Therapeutics, and Kiniksa Pharmaceuticals. Dr. Yeh has research grants from Abbott Vascular, Abiomed, AstraZeneca, Cook, BD Bard, Boston Scientific, Medtronic, and Philips, and consulting fees from Abbott Vascular, AstraZeneca, Boston Scientific, and Medtronic.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material content-type="local-data" id="jah36005-sup-0001">
                <caption>
                  <p>
Tables S1–S3
</p>
                  <p>
Figure S1
</p>
                </caption>
                <media xlink:href="JAH3-10-e018744-s001.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ref-list content-type="cited-references" id="jah36005-bibl-0001">
              <title>References</title>
              <ref id="jah36005-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="jah36005-cit-0001"><string-name><surname>Fröbert</surname><given-names>O</given-names></string-name>, <string-name><surname>Lagerqvist</surname><given-names>BO</given-names></string-name>, <string-name><surname>Olivecrona</surname><given-names>GK</given-names></string-name>, <string-name><surname>Omerovic</surname><given-names>E</given-names></string-name>, <string-name><surname>Gudnason</surname><given-names>T</given-names></string-name>, <string-name><surname>Maeng</surname><given-names>M</given-names></string-name>, <string-name><surname>Aasa</surname><given-names>M</given-names></string-name>, <string-name><surname>Angerås</surname><given-names>O</given-names></string-name>, <string-name><surname>Calais</surname><given-names>F</given-names></string-name>, <string-name><surname>Danielewicz</surname><given-names>M</given-names></string-name>, et al. <article-title>Thrombus aspiration during st‐segment elevation myocardial infarction</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2013</year>;<volume>369</volume>:<fpage>1587</fpage>–<lpage>1597</lpage>. DOI: <pub-id pub-id-type="doi">10.1056/NEJMoa1308789</pub-id>.<pub-id pub-id-type="pmid">23991656</pub-id></mixed-citation>
              </ref>
              <ref id="jah36005-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="jah36005-cit-0002"><string-name><surname>Perez</surname><given-names>MV</given-names></string-name>, <string-name><surname>Mahaffey</surname><given-names>KW</given-names></string-name>, <string-name><surname>Hedlin</surname><given-names>H</given-names></string-name>, <string-name><surname>Rumsfeld</surname><given-names>JS</given-names></string-name>, <string-name><surname>Garcia</surname><given-names>A</given-names></string-name>, <string-name><surname>Ferris</surname><given-names>T</given-names></string-name>, <string-name><surname>Balasubramanian</surname><given-names>V</given-names></string-name>, <string-name><surname>Russo</surname><given-names>AM</given-names></string-name>, <string-name><surname>Rajmane</surname><given-names>A</given-names></string-name>, <string-name><surname>Cheung</surname><given-names>L</given-names></string-name>, et al. <article-title>Large‐scale assessment of a smartwatch to identify atrial fibrillation</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2019</year>;<volume>381</volume>:<fpage>1909</fpage>–<lpage>1917</lpage>. DOI: <pub-id pub-id-type="doi">10.1056/NEJMoa1901183</pub-id>.<pub-id pub-id-type="pmid">31722151</pub-id></mixed-citation>
              </ref>
              <ref id="jah36005-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="miscellaneous" id="jah36005-cit-0003"><collab collab-type="authors">U.S. Food and Drug Administration</collab>
. <article-title>Use of real‐world evidence to support regulatory decision‐making for medical devices: guidance for industry and food and drug administration staff</article-title>. Docket number: Fda‐2016‐d‐2153. <year>2017</year>.</mixed-citation>
              </ref>
              <ref id="jah36005-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="jah36005-cit-0004"><string-name><surname>Choudhry</surname><given-names>NK</given-names></string-name>. <article-title>Randomized, controlled trials in health insurance systems</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2017</year>;<volume>377</volume>:<fpage>957</fpage>–<lpage>964</lpage>. DOI: <pub-id pub-id-type="doi">10.1056/NEJMra1510058</pub-id>.<pub-id pub-id-type="pmid">28877014</pub-id></mixed-citation>
              </ref>
              <ref id="jah36005-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="jah36005-cit-0005"><string-name><surname>Eisenstein</surname><given-names>EL</given-names></string-name>, <string-name><surname>Lemons</surname><given-names>PW</given-names><suffix>2nd</suffix></string-name>, <string-name><surname>Tardiff</surname><given-names>BE</given-names></string-name>, <string-name><surname>Schulman</surname><given-names>KA</given-names></string-name>, <string-name><surname>Jolly</surname><given-names>MK</given-names></string-name>, <string-name><surname>Califf</surname><given-names>RM</given-names></string-name>. <article-title>Reducing the costs of phase III cardiovascular clinical trials</article-title>. <source xml:lang="en">Am Heart J</source>. <year>2005</year>;<volume>149</volume>:<fpage>482</fpage>–<lpage>488</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.ahj.2004.04.049</pub-id>.<pub-id pub-id-type="pmid">15864237</pub-id></mixed-citation>
              </ref>
              <ref id="jah36005-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="jah36005-cit-0006"><string-name><surname>Sertkaya</surname><given-names>A</given-names></string-name>, <string-name><surname>Wong</surname><given-names>HH</given-names></string-name>, <string-name><surname>Jessup</surname><given-names>A</given-names></string-name>, <string-name><surname>Beleche</surname><given-names>T</given-names></string-name>. <article-title>Key cost drivers of pharmaceutical clinical trials in the United States</article-title>. <source xml:lang="en">Clin Trials</source>. <year>2016</year>;<volume>13</volume>:<fpage>117</fpage>–<lpage>126</lpage>. DOI: <pub-id pub-id-type="doi">10.1177/1740774515625964</pub-id>.<pub-id pub-id-type="pmid">26908540</pub-id></mixed-citation>
              </ref>
              <ref id="jah36005-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="jah36005-cit-0007"><string-name><surname>Ruel</surname><given-names>M</given-names></string-name>, <string-name><surname>Falk</surname><given-names>V</given-names></string-name>, <string-name><surname>Farkouh</surname><given-names>ME</given-names></string-name>, <string-name><surname>Freemantle</surname><given-names>N</given-names></string-name>, <string-name><surname>Gaudino</surname><given-names>MF</given-names></string-name>, <string-name><surname>Glineur</surname><given-names>D</given-names></string-name>, <string-name><surname>Cameron</surname><given-names>DE</given-names></string-name>, <string-name><surname>Taggart</surname><given-names>DP</given-names></string-name>. <article-title>Myocardial revascularization trials</article-title>. <source xml:lang="en">Circulation</source>. <year>2018</year>;<volume>138</volume>:<fpage>2943</fpage>–<lpage>2951</lpage>. DOI: <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.118.035970</pub-id>.<pub-id pub-id-type="pmid">30566019</pub-id></mixed-citation>
              </ref>
              <ref id="jah36005-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="jah36005-cit-0008"><string-name><surname>Cho</surname><given-names>MS</given-names></string-name>, <string-name><surname>Ahn</surname><given-names>JM</given-names></string-name>, <string-name><surname>Lee</surname><given-names>CH</given-names></string-name>, <string-name><surname>Kang</surname><given-names>DY</given-names></string-name>, <string-name><surname>Lee</surname><given-names>JB</given-names></string-name>, <string-name><surname>Lee</surname><given-names>PH</given-names></string-name>, <string-name><surname>Kang</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Lee</surname><given-names>SW</given-names></string-name>, <string-name><surname>Kim</surname><given-names>YH</given-names></string-name>, <string-name><surname>Lee</surname><given-names>CW</given-names></string-name>, et al. <article-title>Differential rates and clinical significance of periprocedural myocardial infarction after stenting or bypass surgery for multivessel coronary disease according to various definitions</article-title>. <source xml:lang="en">JACC Cardiovasc Interv</source>. <year>2017</year>;<volume>10</volume>:<fpage>1498</fpage>–<lpage>1507</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.jcin.2017.05.051</pub-id>
<pub-id pub-id-type="pmid">28797425</pub-id></mixed-citation>
              </ref>
              <ref id="jah36005-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="jah36005-cit-0009"><string-name><surname>Ben‐Yehuda</surname><given-names>O</given-names></string-name>, <string-name><surname>Chen</surname><given-names>S</given-names></string-name>, <string-name><surname>Redfors</surname><given-names>B</given-names></string-name>, <string-name><surname>McAndrew</surname><given-names>T</given-names></string-name>, <string-name><surname>Crowley</surname><given-names>A</given-names></string-name>, <string-name><surname>Kosmidou</surname><given-names>I</given-names></string-name>, <string-name><surname>Kandzari</surname><given-names>DE</given-names></string-name>, <string-name><surname>Puskas</surname><given-names>JD</given-names></string-name>, <string-name><surname>Morice</surname><given-names>M‐C</given-names></string-name>, <string-name><surname>Taggart</surname><given-names>DP</given-names></string-name>, et al. <article-title>Impact of large periprocedural myocardial infarction on mortality after percutaneous coronary intervention and coronary artery bypass grafting for left main disease: an analysis from the excel trial</article-title>. <source xml:lang="en">Eur Heart J</source>. <year>2019</year>;<volume>40</volume>:<fpage>1930</fpage>–<lpage>1941</lpage>. DOI: <pub-id pub-id-type="doi">10.1093/eurheartj/ehz113</pub-id>.<pub-id pub-id-type="pmid">30919909</pub-id></mixed-citation>
              </ref>
              <ref id="jah36005-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="jah36005-cit-0010"><string-name><surname>Kazi</surname><given-names>DS</given-names></string-name>, <string-name><surname>Leong</surname><given-names>TK</given-names></string-name>, <string-name><surname>Chang</surname><given-names>TI</given-names></string-name>, <string-name><surname>Solomon</surname><given-names>MD</given-names></string-name>, <string-name><surname>Hlatky</surname><given-names>MA</given-names></string-name>, <string-name><surname>Go</surname><given-names>AS</given-names></string-name>. <article-title>Association of spontaneous bleeding and myocardial infarction with long‐term mortality after percutaneous coronary intervention</article-title>. <source xml:lang="en">J Am Coll Cardiol</source>. <year>2015</year>;<volume>65</volume>:<fpage>1411</fpage>–<lpage>1420</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.jacc.2015.01.047</pub-id>
<pub-id pub-id-type="pmid">25857906</pub-id></mixed-citation>
              </ref>
              <ref id="jah36005-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="jah36005-cit-0011"><string-name><surname>Genereux</surname><given-names>P</given-names></string-name>, <string-name><surname>Giustino</surname><given-names>G</given-names></string-name>, <string-name><surname>Witzenbichler</surname><given-names>B</given-names></string-name>, <string-name><surname>Weisz</surname><given-names>G</given-names></string-name>, <string-name><surname>Stuckey</surname><given-names>TD</given-names></string-name>, <string-name><surname>Rinaldi</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Neumann</surname><given-names>FJ</given-names></string-name>, <string-name><surname>Metzger</surname><given-names>DC</given-names></string-name>, <string-name><surname>Henry</surname><given-names>TD</given-names></string-name>, <string-name><surname>Cox</surname><given-names>DA</given-names></string-name>, et al. <article-title>Incidence, predictors, and impact of post‐discharge bleeding after percutaneous coronary intervention</article-title>. <source xml:lang="en">J Am Coll Cardiol</source>. <year>2015</year>;<volume>66</volume>:<fpage>1036</fpage>–<lpage>1045</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.jacc.2015.06.1323</pub-id>
<pub-id pub-id-type="pmid">26314532</pub-id></mixed-citation>
              </ref>
              <ref id="jah36005-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="jah36005-cit-0012"><string-name><surname>Secemsky</surname><given-names>EA</given-names></string-name>, <string-name><surname>Yeh</surname><given-names>RW</given-names></string-name>, <string-name><surname>Kereiakes</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Cutlip</surname><given-names>DE</given-names></string-name>, <string-name><surname>Cohen</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Steg</surname><given-names>PG</given-names></string-name>, <string-name><surname>Cannon</surname><given-names>CP</given-names></string-name>, <string-name><surname>Apruzzese</surname><given-names>PK</given-names></string-name>, <string-name><surname>D'Agostino</surname><given-names>RB</given-names></string-name>, <string-name><surname>Massaro</surname><given-names>JM</given-names></string-name>, et al. <article-title>Mortality following cardiovascular and bleeding events occurring beyond 1 year after coronary stenting: a secondary analysis of the dual antiplatelet therapy (DAPT) study</article-title>. <source xml:lang="en">JAMA Cardiol</source>. <year>2017</year>;<volume>2</volume>:<fpage>478</fpage>–<lpage>487</lpage>. DOI: <pub-id pub-id-type="doi">10.1001/jamacardio.2017.0063</pub-id>.<pub-id pub-id-type="pmid">28297015</pub-id></mixed-citation>
              </ref>
              <ref id="jah36005-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="jah36005-cit-0013"><string-name><surname>Strom</surname><given-names>JB</given-names></string-name>, <string-name><surname>Tamez‐Aguilar</surname><given-names>H</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>MY</given-names></string-name>, <string-name><surname>Valsdottir</surname><given-names>L</given-names></string-name>, <string-name><surname>Curtis</surname><given-names>J</given-names></string-name>, <string-name><surname>Brennan</surname><given-names>JM</given-names></string-name>, <string-name><surname>Shen</surname><given-names>C</given-names></string-name>, <string-name><surname>Popma</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Mauri</surname><given-names>L</given-names></string-name>, <string-name><surname>Yeh</surname><given-names>RW</given-names></string-name>. <article-title>Validating the use of registries and claims data to support randomized trials: Rationale and design of the extending trial‐based evaluations of medical therapies using novel sources of data (extend) study</article-title>. <source xml:lang="en">Am Heart J</source>. <year>2019</year>;<volume>212</volume>:<fpage>64</fpage>–<lpage>71</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.ahj.2019.02.007</pub-id>.<pub-id pub-id-type="pmid">30953936</pub-id></mixed-citation>
              </ref>
              <ref id="jah36005-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="jah36005-cit-0014"><string-name><surname>Kereiakes</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Yeh</surname><given-names>RW</given-names></string-name>, <string-name><surname>Massaro</surname><given-names>JM</given-names></string-name>, <string-name><surname>Driscoll‐Shempp</surname><given-names>P</given-names></string-name>, <string-name><surname>Cutlip</surname><given-names>DE</given-names></string-name>, <string-name><surname>Steg</surname><given-names>PG</given-names></string-name>, <string-name><surname>Gershlick</surname><given-names>AH</given-names></string-name>, <string-name><surname>Darius</surname><given-names>H</given-names></string-name>, <string-name><surname>Meredith</surname><given-names>IT</given-names></string-name>, <string-name><surname>Ormiston</surname><given-names>J</given-names></string-name>, et al. <article-title>Antiplatelet therapy duration following bare metal or drug‐eluting coronary stents: the dual antiplatelet therapy randomized clinical trial</article-title>. <source xml:lang="en">JAMA</source>. <year>2015</year>;<volume>313</volume>:<fpage>1113</fpage>–<lpage>1121</lpage>. DOI: <pub-id pub-id-type="doi">10.1001/jama.2015.1671</pub-id>.<pub-id pub-id-type="pmid">25781440</pub-id></mixed-citation>
              </ref>
              <ref id="jah36005-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="jah36005-cit-0015"><string-name><surname>Faridi</surname><given-names>KF</given-names></string-name>, <string-name><surname>Tamez</surname><given-names>H</given-names></string-name>, <string-name><surname>Butala</surname><given-names>NM</given-names></string-name>, <string-name><surname>Song</surname><given-names>Y</given-names></string-name>, <string-name><surname>Shen</surname><given-names>C</given-names></string-name>, <string-name><surname>Secemsky</surname><given-names>EA</given-names></string-name>, <string-name><surname>Mauri</surname><given-names>L</given-names></string-name>, <string-name><surname>Curtis</surname><given-names>JP</given-names></string-name>, <string-name><surname>Strom</surname><given-names>JB</given-names></string-name>, <string-name><surname>Yeh</surname><given-names>RW</given-names></string-name>. <article-title>Comparability of event adjudication versus administrative billing claims for outcome ascertainment in the DAPT study: findings from the extend‐DAPT study</article-title>. <source xml:lang="en">Circ Cardiovasc Qual Outcomes</source>. <year>2021</year>;<volume>14</volume>. DOI: <pub-id pub-id-type="doi">10.1161/CIRCOUTCOMES.120.006589</pub-id>.</mixed-citation>
              </ref>
              <ref id="jah36005-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="jah36005-cit-0016"><string-name><surname>Mauri</surname><given-names>L</given-names></string-name>, <string-name><surname>Kereiakes</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Yeh</surname><given-names>RW</given-names></string-name>, <string-name><surname>Driscoll‐Shempp</surname><given-names>P</given-names></string-name>, <string-name><surname>Cutlip</surname><given-names>DE</given-names></string-name>, <string-name><surname>Steg</surname><given-names>PG</given-names></string-name>, <string-name><surname>Normand</surname><given-names>S‐L</given-names></string-name>, <string-name><surname>Braunwald</surname><given-names>E</given-names></string-name>, <string-name><surname>Wiviott</surname><given-names>SD</given-names></string-name>, <string-name><surname>Cohen</surname><given-names>DJ</given-names></string-name>, et al. <article-title>Twelve or 30 months of dual antiplatelet therapy after drug‐eluting stents</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2014</year>;<volume>371</volume>:<fpage>2155</fpage>–<lpage>2166</lpage>. DOI: <pub-id pub-id-type="doi">10.1056/NEJMoa1409312</pub-id>.<pub-id pub-id-type="pmid">25399658</pub-id></mixed-citation>
              </ref>
              <ref id="jah36005-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="journal" id="jah36005-cit-0017"><string-name><surname>Faridi</surname><given-names>KF</given-names></string-name>, <string-name><surname>Tamez</surname><given-names>H</given-names></string-name>, <string-name><surname>Strom</surname><given-names>JB</given-names></string-name>, <string-name><surname>Song</surname><given-names>Y</given-names></string-name>, <string-name><surname>Butala</surname><given-names>NM</given-names></string-name>, <string-name><surname>Shen</surname><given-names>C</given-names></string-name>, <string-name><surname>Secemsky</surname><given-names>EA</given-names></string-name>, <string-name><surname>Mauri</surname><given-names>L</given-names></string-name>, <string-name><surname>Curtis</surname><given-names>JP</given-names></string-name>, <string-name><surname>Gibson</surname><given-names>CM</given-names></string-name>, et al. <article-title>Use of administrative claims data to estimate treatment effects for 30 versus 12 months of dual antiplatelet therapy after percutaneous coronary intervention: findings from the extend‐DAPT study</article-title>. <source xml:lang="en">Circulation</source>. <year>2020</year>;<volume>142</volume>:<fpage>306</fpage>–<lpage>308</lpage>. DOI: <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.120.047729</pub-id>.<pub-id pub-id-type="pmid">32687440</pub-id></mixed-citation>
              </ref>
              <ref id="jah36005-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="journal" id="jah36005-cit-0018"><string-name><surname>Hlatky</surname><given-names>MA</given-names></string-name>, <string-name><surname>Ray</surname><given-names>RM</given-names></string-name>, <string-name><surname>Burwen</surname><given-names>DR</given-names></string-name>, <string-name><surname>Margolis</surname><given-names>KL</given-names></string-name>, <string-name><surname>Johnson</surname><given-names>KC</given-names></string-name>, <string-name><surname>Kucharska‐Newton</surname><given-names>A</given-names></string-name>, <string-name><surname>Manson</surname><given-names>JE</given-names></string-name>, <string-name><surname>Robinson</surname><given-names>JG</given-names></string-name>, <string-name><surname>Safford</surname><given-names>MM</given-names></string-name>, <string-name><surname>Allison</surname><given-names>M</given-names></string-name>. <article-title>Use of medicare data to identify coronary heart disease outcomes in the women's health initiative</article-title>. <source xml:lang="en">Circ Cardiovasc Qual Outcomes</source>. <year>2014</year>;<volume>7</volume>:<fpage>157</fpage>–<lpage>162</lpage>. DOI: <pub-id pub-id-type="doi">10.1161/CIRCOUTCOMES.113.000373</pub-id>
<pub-id pub-id-type="pmid">24399330</pub-id></mixed-citation>
              </ref>
              <ref id="jah36005-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="jah36005-cit-0019"><string-name><surname>Guimaraes</surname><given-names>PO</given-names></string-name>, <string-name><surname>Krishnamoorthy</surname><given-names>A</given-names></string-name>, <string-name><surname>Kaltenbach</surname><given-names>LA</given-names></string-name>, <string-name><surname>Anstrom</surname><given-names>KJ</given-names></string-name>, <string-name><surname>Effron</surname><given-names>MB</given-names></string-name>, <string-name><surname>Mark</surname><given-names>DB</given-names></string-name>, <string-name><surname>McCollam</surname><given-names>PL</given-names></string-name>, <string-name><surname>Davidson‐Ray</surname><given-names>L</given-names></string-name>, <string-name><surname>Peterson</surname><given-names>ED</given-names></string-name>, <string-name><surname>Wang</surname><given-names>TY</given-names></string-name>. <article-title>Accuracy of medical claims for identifying cardiovascular and bleeding events after myocardial infarction: a secondary analysis of the TRANSLATE‐ACS study</article-title>. <source xml:lang="en">JAMA Cardiol</source>. <year>2017</year>;<volume>2</volume>:<fpage>750</fpage>–<lpage>757</lpage>. DOI: <pub-id pub-id-type="doi">10.1001/jamacardio.2017.1460</pub-id>.<pub-id pub-id-type="pmid">28538984</pub-id></mixed-citation>
              </ref>
              <ref id="jah36005-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="journal" id="jah36005-cit-0020"><string-name><surname>Lowenstern</surname><given-names>A</given-names></string-name>, <string-name><surname>Lippmann</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Brennan</surname><given-names>JM</given-names></string-name>, <string-name><surname>Wang</surname><given-names>TY</given-names></string-name>, <string-name><surname>Curtis</surname><given-names>LH</given-names></string-name>, <string-name><surname>Feldman</surname><given-names>T</given-names></string-name>, <string-name><surname>Glower</surname><given-names>DD</given-names></string-name>, <string-name><surname>Hammill</surname><given-names>BG</given-names></string-name>, <string-name><surname>Vemulapalli</surname><given-names>S</given-names></string-name>. <article-title>Use of medicare claims to identify adverse clinical outcomes after mitral valve repair</article-title>. <source xml:lang="en">Circ Cardiovasc Interv</source>. <year>2019</year>;<volume>12</volume>:<elocation-id>e007451</elocation-id>. DOI: <pub-id pub-id-type="doi">10.1161/CIRCINTERVENTIONS.118.007451</pub-id>.<pub-id pub-id-type="pmid">31084236</pub-id></mixed-citation>
              </ref>
              <ref id="jah36005-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="journal" id="jah36005-cit-0021"><string-name><surname>Andrade</surname><given-names>SE</given-names></string-name>, <string-name><surname>Harrold</surname><given-names>LR</given-names></string-name>, <string-name><surname>Tjia</surname><given-names>J</given-names></string-name>, <string-name><surname>Cutrona</surname><given-names>SL</given-names></string-name>, <string-name><surname>Saczynski</surname><given-names>JS</given-names></string-name>, <string-name><surname>Dodd</surname><given-names>KS</given-names></string-name>, <string-name><surname>Goldberg</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Gurwitz</surname><given-names>JH</given-names></string-name>. <article-title>A systematic review of validated methods for identifying cerebrovascular accident or transient ischemic attack using administrative data</article-title>. <source xml:lang="en">Pharmacoepidemiol Drug Saf</source>. <year>2012</year>;<volume>21</volume>:<fpage>100</fpage>–<lpage>128</lpage>. DOI: <pub-id pub-id-type="doi">10.1002/pds.2312</pub-id>
<pub-id pub-id-type="pmid">22262598</pub-id></mixed-citation>
              </ref>
              <ref id="jah36005-bib-0022">
                <label>22</label>
                <mixed-citation publication-type="journal" id="jah36005-cit-0022"><string-name><surname>Yeh</surname><given-names>RW</given-names></string-name>, <string-name><surname>Sidney</surname><given-names>S</given-names></string-name>, <string-name><surname>Chandra</surname><given-names>M</given-names></string-name>, <string-name><surname>Sorel</surname><given-names>M</given-names></string-name>, <string-name><surname>Selby</surname><given-names>JV</given-names></string-name>, <string-name><surname>Go</surname><given-names>AS</given-names></string-name>. <article-title>Population trends in the incidence and outcomes of acute myocardial infarction</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2010</year>;<volume>362</volume>:<fpage>2155</fpage>–<lpage>2165</lpage>. DOI: <pub-id pub-id-type="doi">10.1056/NEJMoa0908610</pub-id>.<pub-id pub-id-type="pmid">20558366</pub-id></mixed-citation>
              </ref>
              <ref id="jah36005-bib-0023">
                <label>23</label>
                <mixed-citation publication-type="journal" id="jah36005-cit-0023"><string-name><surname>Yeh</surname><given-names>RW</given-names></string-name>, <string-name><surname>Secemsky</surname><given-names>EA</given-names></string-name>, <string-name><surname>Kereiakes</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Normand</surname><given-names>S‐L</given-names></string-name>, <string-name><surname>Gershlick</surname><given-names>AH</given-names></string-name>, <string-name><surname>Cohen</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Spertus</surname><given-names>JA</given-names></string-name>, <string-name><surname>Steg</surname><given-names>PG</given-names></string-name>, <string-name><surname>Cutlip</surname><given-names>DE</given-names></string-name>, <string-name><surname>Rinaldi</surname><given-names>MJ</given-names></string-name>, et al. <article-title>Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention</article-title>. <source xml:lang="en">JAMA</source>. <year>2016</year>;<volume>315</volume>:<fpage>1735</fpage>–<lpage>1749</lpage>. DOI: <pub-id pub-id-type="doi">10.1001/jama.2016.3775</pub-id>.<pub-id pub-id-type="pmid">27022822</pub-id></mixed-citation>
              </ref>
              <ref id="jah36005-bib-0024">
                <label>24</label>
                <mixed-citation publication-type="journal" id="jah36005-cit-0024"><string-name><surname>Olivier</surname><given-names>CB</given-names></string-name>, <string-name><surname>Bhatt</surname><given-names>DL</given-names></string-name>, <string-name><surname>Leonardi</surname><given-names>S</given-names></string-name>, <string-name><surname>Stone</surname><given-names>GW</given-names></string-name>, <string-name><surname>Gibson</surname><given-names>CM</given-names></string-name>, <string-name><surname>Steg</surname><given-names>PG</given-names></string-name>, <string-name><surname>Hamm</surname><given-names>CW</given-names></string-name>, <string-name><surname>Wilson</surname><given-names>MD</given-names></string-name>, <string-name><surname>Mangum</surname><given-names>S</given-names></string-name>, <string-name><surname>Price</surname><given-names>MJ</given-names></string-name>, et al. <article-title>Central adjudication identified additional and prognostically important myocardial infarctions in patients undergoing percutaneous coronary intervention</article-title>. <source xml:lang="en">Circ Cardiovasc Interv</source>. <year>2019</year>;<volume>12</volume>:<elocation-id>e007342</elocation-id>. DOI: <pub-id pub-id-type="doi">10.1161/CIRCINTERVENTIONS.118.007342</pub-id>.<pub-id pub-id-type="pmid">31296081</pub-id></mixed-citation>
              </ref>
              <ref id="jah36005-bib-0025">
                <label>25</label>
                <mixed-citation publication-type="journal" id="jah36005-cit-0025"><string-name><surname>Ducrocq</surname><given-names>G</given-names></string-name>, <string-name><surname>Schulte</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Becker</surname><given-names>RC</given-names></string-name>, <string-name><surname>Cannon</surname><given-names>CP</given-names></string-name>, <string-name><surname>Harrington</surname><given-names>RA</given-names></string-name>, <string-name><surname>Held</surname><given-names>C</given-names></string-name>, <string-name><surname>Himmelmann</surname><given-names>A</given-names></string-name>, <string-name><surname>Lassila</surname><given-names>R</given-names></string-name>, <string-name><surname>Storey</surname><given-names>RF</given-names></string-name>, <string-name><surname>Sorbets</surname><given-names>E</given-names></string-name>, et al. <article-title>Association of spontaneous and procedure‐related bleeds with short‐ and long‐term mortality after acute coronary syndromes: an analysis from the plato trial</article-title>. <source xml:lang="en">EuroIntervention</source>. <year>2015</year>;<volume>11</volume>:<fpage>737</fpage>–<lpage>745</lpage>. DOI: <pub-id pub-id-type="doi">10.4244/EIJY14M09_11</pub-id>.<pub-id pub-id-type="pmid">25254357</pub-id></mixed-citation>
              </ref>
              <ref id="jah36005-bib-0026">
                <label>26</label>
                <mixed-citation publication-type="journal" id="jah36005-cit-0026"><string-name><surname>Koskinas</surname><given-names>KC</given-names></string-name>, <string-name><surname>Räber</surname><given-names>L</given-names></string-name>, <string-name><surname>Zanchin</surname><given-names>T</given-names></string-name>, <string-name><surname>Wenaweser</surname><given-names>P</given-names></string-name>, <string-name><surname>Stortecky</surname><given-names>S</given-names></string-name>, <string-name><surname>Moschovitis</surname><given-names>A</given-names></string-name>, <string-name><surname>Khattab</surname><given-names>AA</given-names></string-name>, <string-name><surname>Pilgrim</surname><given-names>T</given-names></string-name>, <string-name><surname>Blöchlinger</surname><given-names>S</given-names></string-name>, <string-name><surname>Moro</surname><given-names>C</given-names></string-name>, et al. <article-title>Clinical impact of gastrointestinal bleeding in patients undergoing percutaneous coronary interventions</article-title>. <source xml:lang="en">Circ Cardiovasc Interv</source>. <year>2015</year>;<volume>8</volume>:<elocation-id>e002053</elocation-id>. DOI: <pub-id pub-id-type="doi">10.1161/CIRCINTERVENTIONS.114.002053</pub-id>.<pub-id pub-id-type="pmid">25910501</pub-id></mixed-citation>
              </ref>
              <ref id="jah36005-bib-0027">
                <label>27</label>
                <mixed-citation publication-type="journal" id="jah36005-cit-0027"><string-name><surname>Psaty</surname><given-names>BM</given-names></string-name>, <string-name><surname>Delaney</surname><given-names>JA</given-names></string-name>, <string-name><surname>Arnold</surname><given-names>AM</given-names></string-name>, <string-name><surname>Curtis</surname><given-names>LH</given-names></string-name>, <string-name><surname>Fitzpatrick</surname><given-names>AL</given-names></string-name>, <string-name><surname>Heckbert</surname><given-names>SR</given-names></string-name>, <string-name><surname>McKnight</surname><given-names>B</given-names></string-name>, <string-name><surname>Ives</surname><given-names>D</given-names></string-name>, <string-name><surname>Gottdiener</surname><given-names>JS</given-names></string-name>, <string-name><surname>Kuller</surname><given-names>LH</given-names></string-name>, et al. <article-title>Study of cardiovascular health outcomes in the era of claims data: the cardiovascular health study</article-title>. <source xml:lang="en">Circulation</source>. <year>2016</year>;<volume>133</volume>:<fpage>156</fpage>–<lpage>164</lpage>. DOI: <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.115.018610</pub-id>.<pub-id pub-id-type="pmid">26538580</pub-id></mixed-citation>
              </ref>
              <ref id="jah36005-bib-0028">
                <label>28</label>
                <mixed-citation publication-type="journal" id="jah36005-cit-0028"><string-name><surname>Guimarães</surname><given-names>PO</given-names></string-name>, <string-name><surname>Krishnamoorthy</surname><given-names>A</given-names></string-name>, <string-name><surname>Kaltenbach</surname><given-names>LA</given-names></string-name>, <string-name><surname>Anstrom</surname><given-names>KJ</given-names></string-name>, <string-name><surname>Effron</surname><given-names>MB</given-names></string-name>, <string-name><surname>Mark</surname><given-names>DB</given-names></string-name>, <string-name><surname>McCollam</surname><given-names>PL</given-names></string-name>, <string-name><surname>Davidson‐Ray</surname><given-names>L</given-names></string-name>, <string-name><surname>Peterson</surname><given-names>ED</given-names></string-name>, <string-name><surname>Wang</surname><given-names>TY</given-names></string-name>. <article-title>Accuracy of medical claims for identifying cardiovascular and bleeding events after myocardial infarction: a secondary analysis of the translate‐acs study</article-title>. <source xml:lang="en">JAMA Cardiol</source>. <year>2017</year>;<volume>2</volume>:<fpage>750</fpage>–<lpage>757</lpage>. DOI: <pub-id pub-id-type="doi">10.1001/jamacardio.2017.1460</pub-id>.<pub-id pub-id-type="pmid">28538984</pub-id></mixed-citation>
              </ref>
              <ref id="jah36005-bib-0029">
                <label>29</label>
                <mixed-citation publication-type="journal" id="jah36005-cit-0029"><string-name><surname>Stone</surname><given-names>GW</given-names></string-name>, <string-name><surname>Kappetein</surname><given-names>AP</given-names></string-name>, <string-name><surname>Sabik</surname><given-names>JF</given-names></string-name>, <string-name><surname>Pocock</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Morice</surname><given-names>M‐C</given-names></string-name>, <string-name><surname>Puskas</surname><given-names>J</given-names></string-name>, <string-name><surname>Kandzari</surname><given-names>DE</given-names></string-name>, <string-name><surname>Karmpaliotis</surname><given-names>D</given-names></string-name>, <string-name><surname>Brown</surname><given-names>WM</given-names></string-name>, <string-name><surname>Lembo</surname><given-names>NJ</given-names></string-name>, et al. <article-title>Five‐year outcomes after PCI or CABG for left main coronary disease</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2019</year>;<volume>381</volume>:<fpage>1820</fpage>–<lpage>1830</lpage>. DOI: <pub-id pub-id-type="doi">10.1056/NEJMoa1909406</pub-id>.<pub-id pub-id-type="pmid">31562798</pub-id></mixed-citation>
              </ref>
              <ref id="jah36005-bib-0030">
                <label>30</label>
                <mixed-citation publication-type="journal" id="jah36005-cit-0030"><string-name><surname>Mahase</surname><given-names>E</given-names></string-name>. <article-title>Surgical association withdraws support for stent advice after controversy over study</article-title>. <source xml:lang="en">BMJ</source>. <year>2019</year>;<volume>367</volume>:<fpage>17006</fpage>. DOI: <pub-id pub-id-type="doi">10.1136/bmj.l7006</pub-id>.</mixed-citation>
              </ref>
              <ref id="jah36005-bib-0031">
                <label>31</label>
                <mixed-citation publication-type="journal" id="jah36005-cit-0031"><string-name><surname>Butala</surname><given-names>NM</given-names></string-name>, <string-name><surname>Strom</surname><given-names>JB</given-names></string-name>, <string-name><surname>Faridi</surname><given-names>KF</given-names></string-name>, <string-name><surname>Kazi</surname><given-names>DS</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>Y</given-names></string-name>, <string-name><surname>Brennan</surname><given-names>JM</given-names></string-name>, <string-name><surname>Popma</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Shen</surname><given-names>C</given-names></string-name>, <string-name><surname>Yeh</surname><given-names>RW</given-names></string-name>. <article-title>Validation of administrative claims to ascertain outcomes in pivotal trials of transcatheter aortic valve replacement</article-title>. <source xml:lang="en">JACC Cardiovasc Interv</source>. <year>2020</year>;<volume>13</volume>:<fpage>1777</fpage>–<lpage>1785</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.jcin.2020.03.049</pub-id>.<pub-id pub-id-type="pmid">32682677</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
